EP4225036A1 - Anti-viral cleaning composition, method of making and use thereof - Google Patents
Anti-viral cleaning composition, method of making and use thereofInfo
- Publication number
- EP4225036A1 EP4225036A1 EP20956890.6A EP20956890A EP4225036A1 EP 4225036 A1 EP4225036 A1 EP 4225036A1 EP 20956890 A EP20956890 A EP 20956890A EP 4225036 A1 EP4225036 A1 EP 4225036A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- absorbent material
- cleaning composition
- virus
- granular absorbent
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 119
- 238000004140 cleaning Methods 0.000 title claims abstract description 114
- 238000004519 manufacturing process Methods 0.000 title description 4
- 230000000840 anti-viral effect Effects 0.000 title description 2
- 239000002250 absorbent Substances 0.000 claims abstract description 146
- 230000002745 absorbent Effects 0.000 claims abstract description 145
- 239000000463 material Substances 0.000 claims abstract description 134
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 112
- 238000000034 method Methods 0.000 claims abstract description 42
- 239000011248 coating agent Substances 0.000 claims abstract description 35
- 238000000576 coating method Methods 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 241000700605 Viruses Species 0.000 claims description 114
- 230000003115 biocidal effect Effects 0.000 claims description 32
- 239000003139 biocide Substances 0.000 claims description 32
- 239000004094 surface-active agent Substances 0.000 claims description 24
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 20
- 239000000919 ceramic Substances 0.000 claims description 19
- 238000005202 decontamination Methods 0.000 claims description 18
- 230000003588 decontaminative effect Effects 0.000 claims description 17
- 241000711573 Coronaviridae Species 0.000 claims description 16
- 239000007921 spray Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 12
- 239000011707 mineral Substances 0.000 claims description 12
- 241001678559 COVID-19 virus Species 0.000 claims description 11
- 239000010457 zeolite Substances 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000003945 anionic surfactant Substances 0.000 claims description 9
- 241001263478 Norovirus Species 0.000 claims description 8
- 229910021536 Zeolite Inorganic materials 0.000 claims description 8
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 8
- 241000712891 Arenavirus Species 0.000 claims description 6
- 229910021485 fumed silica Inorganic materials 0.000 claims description 6
- 241000150452 Orthohantavirus Species 0.000 claims description 5
- 241000702670 Rotavirus Species 0.000 claims description 5
- 230000002070 germicidal effect Effects 0.000 claims description 5
- 241001115402 Ebolavirus Species 0.000 claims description 4
- 241000711950 Filoviridae Species 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000007740 vapor deposition Methods 0.000 claims description 4
- 241000526636 Nipah henipavirus Species 0.000 claims description 3
- 241000713112 Orthobunyavirus Species 0.000 claims description 3
- 230000000845 anti-microbial effect Effects 0.000 claims description 3
- 244000309743 astrovirus Species 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 210000002249 digestive system Anatomy 0.000 claims description 2
- 210000005096 hematological system Anatomy 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 210000002346 musculoskeletal system Anatomy 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- 244000052769 pathogen Species 0.000 abstract description 15
- 210000001124 body fluid Anatomy 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 2
- 239000000383 hazardous chemical Substances 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 230000002599 biostatic effect Effects 0.000 abstract 1
- 238000005108 dry cleaning Methods 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 94
- 210000004027 cell Anatomy 0.000 description 38
- -1 tiles Substances 0.000 description 30
- 239000000126 substance Substances 0.000 description 28
- 239000000645 desinfectant Substances 0.000 description 25
- 238000010790 dilution Methods 0.000 description 25
- 239000012895 dilution Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 22
- 239000000969 carrier Substances 0.000 description 21
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 17
- 239000012091 fetal bovine serum Substances 0.000 description 17
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 16
- 239000006143 cell culture medium Substances 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 239000012467 final product Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 13
- 230000000120 cytopathologic effect Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 13
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 241001138501 Salmonella enterica Species 0.000 description 11
- 150000001412 amines Chemical group 0.000 description 11
- 239000007791 liquid phase Substances 0.000 description 11
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 10
- 235000010755 mineral Nutrition 0.000 description 10
- 239000010451 perlite Substances 0.000 description 10
- 235000019362 perlite Nutrition 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 241000714201 Feline calicivirus Species 0.000 description 9
- 239000002054 inoculum Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 8
- 235000019270 ammonium chloride Nutrition 0.000 description 8
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 8
- 231100000481 chemical toxicant Toxicity 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 8
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 230000007613 environmental effect Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 229910052709 silver Inorganic materials 0.000 description 8
- 239000004332 silver Substances 0.000 description 8
- 239000003440 toxic substance Substances 0.000 description 8
- 230000003253 viricidal effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 7
- 229910052802 copper Inorganic materials 0.000 description 7
- 239000010949 copper Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 238000004710 electron pair approximation Methods 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000010455 vermiculite Substances 0.000 description 7
- 229910052902 vermiculite Inorganic materials 0.000 description 7
- 235000019354 vermiculite Nutrition 0.000 description 7
- 210000002845 virion Anatomy 0.000 description 7
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 6
- 241000531123 GB virus C Species 0.000 description 6
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 229960002163 hydrogen peroxide Drugs 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 150000004756 silanes Chemical class 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- 241000193163 Clostridioides difficile Species 0.000 description 5
- 208000001528 Coronaviridae Infections Diseases 0.000 description 5
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000013553 cell monolayer Substances 0.000 description 5
- 229940044683 chemotherapy drug Drugs 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000123 paper Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000003068 static effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 description 4
- 208000025721 COVID-19 Diseases 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000714214 Feline calicivirus strain F9 Species 0.000 description 4
- 208000005577 Gastroenteritis Diseases 0.000 description 4
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 4
- 241000315672 SARS coronavirus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000004779 membrane envelope Anatomy 0.000 description 4
- 229910000000 metal hydroxide Inorganic materials 0.000 description 4
- 150000004692 metal hydroxides Chemical class 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000000474 nursing effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 229920001296 polysiloxane Chemical class 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 210000004916 vomit Anatomy 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 3
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 241000607768 Shigella Species 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- MCMNRKCIXSYSNV-UHFFFAOYSA-N ZrO2 Inorganic materials O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000249 desinfective effect Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000013100 final test Methods 0.000 description 3
- 229960000587 glutaral Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- LTPBRCUWZOMYOC-UHFFFAOYSA-N Beryllium oxide Chemical compound O=[Be] LTPBRCUWZOMYOC-UHFFFAOYSA-N 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- 241001136175 Burkholderia pseudomallei Species 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 239000004155 Chlorine dioxide Substances 0.000 description 2
- 208000037384 Clostridium Infections Diseases 0.000 description 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 2
- 206010054236 Clostridium difficile infection Diseases 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 description 2
- 241000223935 Cryptosporidium Species 0.000 description 2
- RUPBZQFQVRMKDG-UHFFFAOYSA-M Didecyldimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC RUPBZQFQVRMKDG-UHFFFAOYSA-M 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000724675 Hepatitis E virus Species 0.000 description 2
- 241000724709 Hepatitis delta virus Species 0.000 description 2
- 241000228404 Histoplasma capsulatum Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 2
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 2
- 241000701027 Human herpesvirus 6 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 241000342334 Human metapneumovirus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 241000702617 Human parvovirus B19 Species 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 241001115401 Marburgvirus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 239000012425 OXONE® Substances 0.000 description 2
- 229920003171 Poly (ethylene oxide) Chemical class 0.000 description 2
- 241000713124 Rift Valley fever virus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 241000194049 Streptococcus equinus Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- 241000223229 Trichophyton rubrum Species 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 2
- 241000710886 West Nile virus Species 0.000 description 2
- 241000710772 Yellow fever virus Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 235000019398 chlorine dioxide Nutrition 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000002563 ionic surfactant Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 201000000626 mucocutaneous leishmaniasis Diseases 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- LMXFTMYMHGYJEI-UHFFFAOYSA-N p-menthane-3,8-diol Chemical compound CC1CCC(C(C)(C)O)C(O)C1 LMXFTMYMHGYJEI-UHFFFAOYSA-N 0.000 description 2
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229920005573 silicon-containing polymer Polymers 0.000 description 2
- BSWGGJHLVUUXTL-UHFFFAOYSA-N silver zinc Chemical compound [Zn].[Ag] BSWGGJHLVUUXTL-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 229920000247 superabsorbent polymer Polymers 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- 229960001479 tosylchloramide sodium Drugs 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 229940051021 yellow-fever virus Drugs 0.000 description 2
- IFKPLJWIEQBPGG-QGZVFWFLSA-N (5s)-6-(dimethylamino)-5-methyl-4,4-diphenylhexan-3-one Chemical compound C=1C=CC=CC=1C([C@H](C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-QGZVFWFLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- UNWRHVZXVVTASG-UHFFFAOYSA-N 1,3-dichloro-1,3,5-triazinane-2,4,6-trione;sodium Chemical compound [Na].ClN1C(=O)NC(=O)N(Cl)C1=O UNWRHVZXVVTASG-UHFFFAOYSA-N 0.000 description 1
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- UUIVKBHZENILKB-UHFFFAOYSA-N 2,2-dibromo-2-cyanoacetamide Chemical compound NC(=O)C(Br)(Br)C#N UUIVKBHZENILKB-UHFFFAOYSA-N 0.000 description 1
- GJWZTZWDFBKFHI-UHFFFAOYSA-N 2-[n'-[6-[[amino-(diaminomethylideneamino)methylidene]amino]hexyl]carbamimidoyl]-1,3-bis(4-chlorophenyl)guanidine Chemical compound C=1C=C(Cl)C=CC=1N=C(NC(=N)NCCCCCCNC(=N)NC(=N)N)NC1=CC=C(Cl)C=C1 GJWZTZWDFBKFHI-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- WBIQQQGBSDOWNP-UHFFFAOYSA-N 2-dodecylbenzenesulfonic acid Chemical compound CCCCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O WBIQQQGBSDOWNP-UHFFFAOYSA-N 0.000 description 1
- WFUGQJXVXHBTEM-UHFFFAOYSA-N 2-hydroperoxy-2-(2-hydroperoxybutan-2-ylperoxy)butane Chemical compound CCC(C)(OO)OOC(C)(CC)OO WFUGQJXVXHBTEM-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- DSSAWHFZNWVJEC-UHFFFAOYSA-N 3-(ethenoxymethyl)heptane Chemical compound CCCCC(CC)COC=C DSSAWHFZNWVJEC-UHFFFAOYSA-N 0.000 description 1
- RVKPQXGYBPTWPT-UHFFFAOYSA-N 3-methylhexane-2,2-diol Chemical compound CCCC(C)C(C)(O)O RVKPQXGYBPTWPT-UHFFFAOYSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- UZJGVXSQDRSSHU-UHFFFAOYSA-N 6-(1,3-dioxoisoindol-2-yl)hexaneperoxoic acid Chemical compound C1=CC=C2C(=O)N(CCCCCC(=O)OO)C(=O)C2=C1 UZJGVXSQDRSSHU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 229910052582 BN Inorganic materials 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000537222 Betabaculovirus Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 241001148106 Brucella melitensis Species 0.000 description 1
- 241001148111 Brucella suis Species 0.000 description 1
- 241000722910 Burkholderia mallei Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 241000191796 Calyptosphaeria tropica Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241001307956 Chorioptes bovis Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241001522132 Corynebacterium pseudodiphtheriticum Species 0.000 description 1
- 241000186225 Corynebacterium pseudotuberculosis Species 0.000 description 1
- 241000918600 Corynebacterium ulcerans Species 0.000 description 1
- 241000158520 Corynebacterium urealyticum Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- 241000179197 Cyclospora Species 0.000 description 1
- 241000205707 Cystoisospora belli Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 241000725618 Duck hepatitis B virus Species 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N E-Sorbic acid Chemical compound C\C=C\C=C\C(O)=O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005804 Eastern equine encephalitis Diseases 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 208000032163 Emerging Communicable disease Diseases 0.000 description 1
- 206010014587 Encephalitis eastern equine Diseases 0.000 description 1
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000223682 Exophiala Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000222740 Leishmania braziliensis Species 0.000 description 1
- 241000178949 Leishmania chagasi Species 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 241000222696 Leishmania guyanensis Species 0.000 description 1
- 241000222697 Leishmania infantum Species 0.000 description 1
- 241000222695 Leishmania panamensis Species 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 244000011376 Leptospermum laevigatum Species 0.000 description 1
- 235000017865 Leptospermum laevigatum Nutrition 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241000407429 Maja Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000378467 Melaleuca Species 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 241001299895 Microsporum ferrugineum Species 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- NXTVQNIVUKXOIL-UHFFFAOYSA-N N-chlorotoluene-p-sulfonamide Chemical compound CC1=CC=C(S(=O)(=O)NCl)C=C1 NXTVQNIVUKXOIL-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 241000893974 Nannizzia fulva Species 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 241000264375 Nannizzia nana Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241000187678 Nocardia asteroides Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 244000020186 Nymphaea lutea Species 0.000 description 1
- 244000218514 Opuntia robusta Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- CVXHBROPWMVEQO-UHFFFAOYSA-N Peroxyoctanoic acid Chemical compound CCCCCCCC(=O)OO CVXHBROPWMVEQO-UHFFFAOYSA-N 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 240000009188 Phyllostachys vivax Species 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 241001326501 Piedraia Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 241000142787 Pneumocystis jirovecii Species 0.000 description 1
- 241000711904 Pneumoviridae Species 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000005822 Propiconazole Substances 0.000 description 1
- 241000334216 Proteus sp. Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000221535 Pucciniales Species 0.000 description 1
- 101710200092 Replicase polyprotein Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000606697 Rickettsia prowazekii Species 0.000 description 1
- 241000533331 Salmonella bongori Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000223598 Scedosporium boydii Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607766 Shigella boydii Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 229910007159 Si(CH3)4 Inorganic materials 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241001149963 Sporothrix schenckii Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194008 Streptococcus anginosus Species 0.000 description 1
- 241000194007 Streptococcus canis Species 0.000 description 1
- 241000194048 Streptococcus equi Species 0.000 description 1
- 241001134658 Streptococcus mitis Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- 241000045663 Trematosphaeria grisea Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000680598 Treponema pedis Species 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241000893962 Trichophyton equinum Species 0.000 description 1
- 241001045773 Trichophyton erinacei Species 0.000 description 1
- 241001459572 Trichophyton interdigitale Species 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 241000985906 Trichophyton soudanense Species 0.000 description 1
- 241001480048 Trichophyton tonsurans Species 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 241001480050 Trichophyton violaceum Species 0.000 description 1
- 241001621834 Trichophyton yaoundei Species 0.000 description 1
- 241000223231 Trichosporon beigelii Species 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 241000221561 Ustilaginales Species 0.000 description 1
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 1
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000028227 Viral hemorrhagic fever Diseases 0.000 description 1
- 241000710951 Western equine encephalitis virus Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PZKRHHZKOQZHIO-UHFFFAOYSA-N [B].[B].[Mg] Chemical compound [B].[B].[Mg] PZKRHHZKOQZHIO-UHFFFAOYSA-N 0.000 description 1
- WZECUPJJEIXUKY-UHFFFAOYSA-N [O-2].[O-2].[O-2].[U+6] Chemical compound [O-2].[O-2].[O-2].[U+6] WZECUPJJEIXUKY-UHFFFAOYSA-N 0.000 description 1
- OSOKRZIXBNTTJX-UHFFFAOYSA-N [O].[Ca].[Cu].[Sr].[Bi] Chemical compound [O].[Ca].[Cu].[Sr].[Bi] OSOKRZIXBNTTJX-UHFFFAOYSA-N 0.000 description 1
- BTGZYWWSOPEHMM-UHFFFAOYSA-N [O].[Cu].[Y].[Ba] Chemical compound [O].[Cu].[Y].[Ba] BTGZYWWSOPEHMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 244000000022 airborne pathogen Species 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 229940115440 aluminum sodium silicate Drugs 0.000 description 1
- JEWHCPOELGJVCB-UHFFFAOYSA-N aluminum;calcium;oxido-[oxido(oxo)silyl]oxy-oxosilane;potassium;sodium;tridecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.[Na].[Al].[K].[Ca].[O-][Si](=O)O[Si]([O-])=O JEWHCPOELGJVCB-UHFFFAOYSA-N 0.000 description 1
- JYIBXUUINYLWLR-UHFFFAOYSA-N aluminum;calcium;potassium;silicon;sodium;trihydrate Chemical compound O.O.O.[Na].[Al].[Si].[K].[Ca] JYIBXUUINYLWLR-UHFFFAOYSA-N 0.000 description 1
- 210000002588 alveolar type II cell Anatomy 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 229910052908 analcime Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229910002113 barium titanate Inorganic materials 0.000 description 1
- JRPBQTZRNDNNOP-UHFFFAOYSA-N barium titanate Chemical compound [Ba+2].[Ba+2].[O-][Ti]([O-])([O-])[O-] JRPBQTZRNDNNOP-UHFFFAOYSA-N 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001574 benzoxonium chloride Drugs 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910052810 boron oxide Inorganic materials 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 229940074375 burkholderia mallei Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- MCFVRESNTICQSJ-RJNTXXOISA-L calcium sorbate Chemical compound [Ca+2].C\C=C\C=C\C([O-])=O.C\C=C\C=C\C([O-])=O MCFVRESNTICQSJ-RJNTXXOISA-L 0.000 description 1
- UNYSKUBLZGJSLV-UHFFFAOYSA-L calcium;1,3,5,2,4,6$l^{2}-trioxadisilaluminane 2,4-dioxide;dihydroxide;hexahydrate Chemical compound O.O.O.O.O.O.[OH-].[OH-].[Ca+2].O=[Si]1O[Al]O[Si](=O)O1.O=[Si]1O[Al]O[Si](=O)O1 UNYSKUBLZGJSLV-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- CGMKPKRNUNDACU-UHFFFAOYSA-N carbamimidoyl(dodecyl)azanium;chloride Chemical compound Cl.CCCCCCCCCCCCN=C(N)N CGMKPKRNUNDACU-UHFFFAOYSA-N 0.000 description 1
- HLKHRRVTJUCBFZ-UHFFFAOYSA-N carbamimidoyl-[2-(2-ethoxyethoxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOCCOCC[NH2+]C(N)=N HLKHRRVTJUCBFZ-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- CETPSERCERDGAM-UHFFFAOYSA-N ceric oxide Chemical compound O=[Ce]=O CETPSERCERDGAM-UHFFFAOYSA-N 0.000 description 1
- 229910000422 cerium(IV) oxide Inorganic materials 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- 229910052676 chabazite Inorganic materials 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960005443 chloroxylenol Drugs 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 239000009854 citriodiol Substances 0.000 description 1
- 229910001603 clinoptilolite Inorganic materials 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 239000013552 cultured cell monolayer Substances 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- JKWMSGQKBLHBQQ-UHFFFAOYSA-N diboron trioxide Chemical compound O=BOB=O JKWMSGQKBLHBQQ-UHFFFAOYSA-N 0.000 description 1
- 229960004670 didecyldimethylammonium chloride Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- RDMZIKMKSGCBKK-UHFFFAOYSA-N disodium;(9,11-dioxido-5-oxoboranyloxy-2,4,6,8,10,12,13-heptaoxa-1,3,5,7,9,11-hexaborabicyclo[5.5.1]tridecan-3-yl)oxy-oxoborane;tetrahydrate Chemical compound O.O.O.O.[Na+].[Na+].O1B(OB=O)OB(OB=O)OB2OB([O-])OB([O-])OB1O2 RDMZIKMKSGCBKK-UHFFFAOYSA-N 0.000 description 1
- AJFXNBUVIBKWBT-UHFFFAOYSA-N disodium;boric acid;hydrogen borate Chemical compound [Na+].[Na+].OB(O)O.OB(O)O.OB(O)O.OB([O-])[O-] AJFXNBUVIBKWBT-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940060296 dodecylbenzenesulfonic acid Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 229910052571 earthenware Inorganic materials 0.000 description 1
- 230000000678 effect on lipid Effects 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- OYQYHJRSHHYEIG-UHFFFAOYSA-N ethyl carbamate;urea Chemical compound NC(N)=O.CCOC(N)=O OYQYHJRSHHYEIG-UHFFFAOYSA-N 0.000 description 1
- UUHBNESUDPIHCI-UHFFFAOYSA-M ethyl-hexadecyl-dimethylazanium;ethyl sulfate Chemical compound CCOS([O-])(=O)=O.CCCCCCCCCCCCCCCC[N+](C)(C)CC UUHBNESUDPIHCI-UHFFFAOYSA-M 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- ASKSDLRLUXEOOR-SUFRFZPQSA-N gbv-c Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC(C)C)=CNC2=C1 ASKSDLRLUXEOOR-SUFRFZPQSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 229910052677 heulandite Inorganic materials 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical class Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940035535 iodophors Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052451 lead zirconate titanate Inorganic materials 0.000 description 1
- HFGPZNIAWCZYJU-UHFFFAOYSA-N lead zirconate titanate Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Ti+4].[Zr+4].[Pb+2] HFGPZNIAWCZYJU-UHFFFAOYSA-N 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 150000005451 methyl sulfates Chemical class 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 125000005609 naphthenate group Chemical group 0.000 description 1
- 229910052674 natrolite Inorganic materials 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000004767 nitrides Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 239000005332 obsidian Substances 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-O octylazanium Chemical compound CCCCCCCC[NH3+] IOQPZZOEVPZRBK-UHFFFAOYSA-O 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000003961 organosilicon compounds Chemical class 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229910002077 partially stabilized zirconia Inorganic materials 0.000 description 1
- HJKYXKSLRZKNSI-UHFFFAOYSA-I pentapotassium;hydrogen sulfate;oxido sulfate;sulfuric acid Chemical compound [K+].[K+].[K+].[K+].[K+].OS([O-])(=O)=O.[O-]S([O-])(=O)=O.OS(=O)(=O)O[O-].OS(=O)(=O)O[O-] HJKYXKSLRZKNSI-UHFFFAOYSA-I 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229910001743 phillipsite Inorganic materials 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052615 phyllosilicate Inorganic materials 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000212 poly(isobutyl acrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- CHHHXKFHOYLYRE-STWYSWDKSA-M potassium sorbate Chemical compound [K+].C\C=C\C=C\C([O-])=O CHHHXKFHOYLYRE-STWYSWDKSA-M 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- STJLVHWMYQXCPB-UHFFFAOYSA-N propiconazole Chemical compound O1C(CCC)COC1(C=1C(=CC(Cl)=CC=1)Cl)CN1N=CN=C1 STJLVHWMYQXCPB-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PXGPLTODNUVGFL-JZFBHDEDSA-N prostaglandin F2beta Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-JZFBHDEDSA-N 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000008262 pumice Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940046939 rickettsia prowazekii Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 229910021332 silicide Inorganic materials 0.000 description 1
- FVBUAEGBCNSCDD-UHFFFAOYSA-N silicide(4-) Chemical compound [Si-4] FVBUAEGBCNSCDD-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- KIIUTKAWYISOAM-UHFFFAOYSA-N silver sodium Chemical compound [Na].[Ag] KIIUTKAWYISOAM-UHFFFAOYSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 235000012217 sodium aluminium silicate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- MSFGZHUJTJBYFA-UHFFFAOYSA-M sodium dichloroisocyanurate Chemical compound [Na+].ClN1C(=O)[N-]C(=O)N(Cl)C1=O MSFGZHUJTJBYFA-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- PYILKOIEIHHYGD-UHFFFAOYSA-M sodium;1,5-dichloro-4,6-dioxo-1,3,5-triazin-2-olate;dihydrate Chemical compound O.O.[Na+].[O-]C1=NC(=O)N(Cl)C(=O)N1Cl PYILKOIEIHHYGD-UHFFFAOYSA-M 0.000 description 1
- YOYVXVLOSQBCMA-UHFFFAOYSA-M sodium;2-phenylbenzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC=C1 YOYVXVLOSQBCMA-UHFFFAOYSA-M 0.000 description 1
- DPHAGKRZIJHMNL-UHFFFAOYSA-M sodium;4-chloro-3-methylphenolate Chemical compound [Na+].CC1=CC([O-])=CC=C1Cl DPHAGKRZIJHMNL-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229910052678 stilbite Inorganic materials 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- VEALVRVVWBQVSL-UHFFFAOYSA-N strontium titanate Chemical compound [Sr+2].[O-][Ti]([O-])=O VEALVRVVWBQVSL-UHFFFAOYSA-N 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000004583 superabsorbent polymers (SAPs) Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- MSLRPWGRFCKNIZ-UHFFFAOYSA-J tetrasodium;hydrogen peroxide;dicarbonate Chemical compound [Na+].[Na+].[Na+].[Na+].OO.OO.OO.[O-]C([O-])=O.[O-]C([O-])=O MSLRPWGRFCKNIZ-UHFFFAOYSA-J 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- ZDHXKXAHOVTTAH-UHFFFAOYSA-N trichlorosilane Chemical compound Cl[SiH](Cl)Cl ZDHXKXAHOVTTAH-UHFFFAOYSA-N 0.000 description 1
- 239000005052 trichlorosilane Substances 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- MTPVUVINMAGMJL-UHFFFAOYSA-N trimethyl(1,1,2,2,2-pentafluoroethyl)silane Chemical compound C[Si](C)(C)C(F)(F)C(F)(F)F MTPVUVINMAGMJL-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229910000439 uranium oxide Inorganic materials 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000012873 virucide Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000005335 volcanic glass Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910021521 yttrium barium copper oxide Inorganic materials 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
- LEHFSLREWWMLPU-UHFFFAOYSA-B zirconium(4+);tetraphosphate Chemical compound [Zr+4].[Zr+4].[Zr+4].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LEHFSLREWWMLPU-UHFFFAOYSA-B 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/12—Powders or granules
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
- C11D17/0039—Coated compositions or coated components in the compositions, (micro)capsules
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
- C11D17/04—Detergent materials or soaps characterised by their shape or physical properties combined with or containing other objects
- C11D17/049—Cleaning or scouring pads; Wipes
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/02—Inorganic compounds ; Elemental compounds
- C11D3/12—Water-insoluble compounds
- C11D3/124—Silicon containing, e.g. silica, silex, quartz or glass beads
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present application generally relates to a cleaning compositions and methods and, in particular, relates to a cleaning composition and method for cleaning up a virus, or other pathogens, on a surface, such as disinfecting, or removing viral particles from, a public area.
- One aspect of the present application is directed to a method of formulating a cleaning composition to decontaminate surfaces contaminated by a virus, comprising the steps of: coating a granular absorbent material with a coating agent to produce a coated absorbent material; and mixing the coated absorbent material with a sanitation agent, wherein the coated absorbent material absorbs the sanitation agent to form the cleaning composition, wherein the sanitation agent comprises a surfactant.
- the granular absorbent material is coated with a layer of surface bonded biocide by vapor deposition, pressure micro droplet spray or fuming or fogging nozzle.
- the granular absorbent material is selected from the group consisting of ceramic minerals, zeolite, activated carbon, fumed silica, processed clays, cellulosic absorbents, fibrous absorbents and combinations thereof.
- the granular absorbent material comprises ceramic minerals.
- the ceramic minerals comprise perlite and/or vermiculite.
- the coating agent comprises a biocide.
- the coating agent forms a surface bonded film on the granular absorbent material.
- the sanitation agent is an anionic surfactant.
- Another aspect of the application is a method for prevention and/or decontamination of a surface from a virus, comprising: applying an effective amount of cleaning composition on said surface, wherein said cleaning composition comprises an granular absorbent material coated with a biocide; and a sanitation agent absorbed in said granular absorbent material, wherein said sanitation agent comprises a surfactant.
- the virus is norovirus, HIV, rotavirus, adenovirus, astrovirus, coronavirus, hepatitis virus, ebola or norovirus, arenaviruses, bunyaviruses, filoviruses, arenaviruses, Nipah virus or hantavirus.
- the coronavirus is SARS-CoV-2.
- a cleaning composition for decontamination against viruses comprising: a granular absorbent material coated with a biocide; and a sanitation agent absorbed in said granular absorbent material, wherein said sanitation agent comprises a surfactant.
- the granular absorbent material is selected from the group consisting of ceramic minerals, zeolite, activated carbon, fumed silica, processed clays, cellulosic absorbents, fibrous absorbents and combinations thereof.
- the granular absorbent material comprises ceramic minerals.
- the ceramic minerals comprise perlite and/or vermiculite.
- the biocide forms a surface bonded film on the granular absorbent material.
- Another aspect of the application is a sanitation method for decontamination against viruses, comprising the step of: applying an effective amount of a cleaning composition a cleaning composition for decontamination against viruses, comprising: an granular absorbent material coated with a biocide; and a sanitation agent absorbed in said granular absorbent material, wherein said sanitation agent comprises a surfactant to a surface in need of sanitation; and removing the cleaning composition after a period of time.
- a cleaning composition for decontamination against viruses comprising: applying an effective amount of a cleaning composition a cleaning composition for decontamination against viruses, comprising: an granular absorbent material coated with a biocide; and a sanitation agent absorbed in said granular absorbent material, wherein said sanitation agent comprises a surfactant to a surface in need of sanitation; and removing the cleaning composition after a period of time.
- a cleaning kit for decontaminating against viruses comprising: a cleaning composition a cleaning composition for decontamination against viruses, comprising: an granular absorbent material coated with a biocide; and a sanitation agent absorbed in said granular absorbent material, wherein said sanitation agent comprises a surfactant, and instructions on how to use the cleaning composition.
- a cleaning composition for decontamination against viruses, comprising: an granular absorbent material coated with a biocide; and a sanitation agent absorbed in said granular absorbent material, wherein said sanitation agent comprises a surfactant, and instructions on how to use the cleaning composition.
- a cleaning composition for decontamination against viruses comprising: an granular absorbent material coated with a biocide; and a sanitation agent absorbed in said granular absorbent material, wherein said sanitation agent comprises a surfactant, and instructions on how to use the cleaning composition.
- said sanitation agent comprises a surfactant
- Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it is understood that the particular value forms another embodiment. It is further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed.
- This application describes a novel, effective and low cost cleaning composition that can be used for rapid and safe clean-up of a surface contaminated by viruses through biohazard spills (vomit / urine / blood and feces) in hospitals, urgent care facilities, medical offices, nursing homes, prisons, schools and the hospitality industry. Viruses may have also contaminated the environment though coughing, sneezing, spitting, or other sources of respiratory droplets carrying viral load. References to pathogens herein should be understood to encompass viruses.
- the cleaning composition of the present application is a multi-phase product that can be used to kill viruses through a number of different mechanisms by either disrupting the viral proteins, or in certain instances the viral envelope.
- the composition is a doped granular ceramic disinfectant which combines a surface area static disinfectant or biocide coating with a chemical phase primary disinfectant (e.g. surfactant) or biocide absorbed in the ceramic particles.
- the multi-phase product provides an effective means to decontaminate surfaces of viruses by acting as a delivery platform for a multi-pronged attack on the integrity of the virus.
- the cleaning composition of the present application and the method of use thereof are designed to kill or inactivate enveloped viruses, such as coronaviruses.
- Viruses may include viruses that can effect one or more of the nervous system, musculo-skeletal system, digestive system, hematological systems, immune systems, or respiratory systems.
- viruses include, but are not limited to, influenza viruses, herpesviruses, polioviruses, noroviruses, gastrointestinal tract-related (Gl-related) viruses, retroviruses, human immunodeficiency virus type 1 and type 2 (HIV-1 and HIV-2), human T- cell lymphotropic virus type I and type II (HTLV-I and HTLV-II), hepatitis A virus, hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis delta virus (HDV), hepatitis E virus (HEV), hepatitis G virus (HGV), parvovirus B19 virus, transfusion transmitted virus (TTV), Epstein- Barr virus, human cytomegalovirus type 1 (HCMV-1), human herpesvirus type 6 (HHV-6), human
- Examples of microbes caused causing gastroenteritis in man and animals include, viruses, bacteria, parasites and fungus. Viruses cause ⁇ 7-% of infectious diarrhea. Viral infections causing gastroenteritis can be attributed to rotavirus, adenovirus, norovirus, astrovirus, and coronavirus.
- Enveloped viruses are usually inactivated by effective surface cleaning and disinfection. Enveloped viruses possess an envelope composed of a lipid layer (fat-like substance that is water insoluble) that forms an outer coating. The virus envelope is required for attachment of the virus to a target cell. The lipid layers in cellular membranes are impermeable to most polar or charged solutes but are permeable to apolar compounds, such as the lipids making up a viral envelope. Individual enveloped viruses have differing modes of transmission; however, typical routes of transmission are via indirect or direct bodily contact with infectious virus particles, such as by inhalation or contact with respiratory droplets carrying a viral load.
- enveloped viruses are more readily inactivated by most chemical disinfectants than are nonenveloped viruses. Although the mechanisms of virus inactivation by chemicals is poorly understood, lipophilic disinfectants and chaotropic agents should have little difficulty in breaching a normal lipid bilayer. Thus, it is likely that the infectivity of enveloped viruses could be destroyed with little or no direct damage to the protein or nucleic acid of the virus. However, it is not known how much damage must be done to the virus envelope before virus infection is prevented. At high surfactant concentrations, damage to the proteins and nucleic acids of the virion is also likely.
- One aspect of the present application is directed to a method of making a cleaning composition.
- the method comprises the steps of coating a granular absorbent material with a coating agent to produce a coated absorbent material; and mixing the coated absorbent material with a sanitation agent, wherein the coated absorbent material absorbs the sanitation agent to form a coated and absorbed absorbent material.
- the method further comprises the step of grinding an absorbent material to produce the granular absorbent material used in the coating step.
- the method further comprises the step of adding one or more modifying agent to the coated and absorbed absorbent material in amounts sufficient to achieve desired physical characteristics (e.g, non-dusty and clump, ease of pick up, liquid loading capacity, etc.).
- the cleaning composition may be used to eradicate, eliminate, inactivate, inhibit the activity of, or reduce the amount of pathogens on a surface.
- the cleaning composition is especially for the clean-up of biohazard spills, such as vomit, urine, blood and feces in hospitals, urgent care facilities, medical offices, nursing homes, prisons, schools and the hospitality industry.
- the cleaning composition of the present application is also ideally suited for clean-up of common, highly hazardous spills in these environments, such as spills of chemotherapy drugs.
- the Granular Absorbent Material can be any solid material with desired surface area, granulation, and absorbent characteristics.
- the term “absorbent” or “adsorbent” is understood to mean a material that is capable of imbibing and holding onto aqueous fluids.
- Suitable granular absorbent material include, but are not limited to, expanded and optimized ceramic minerals such perlite and vermiculite, zeolite, activated carbon, cellulosic absorbents and fibrous absorbents.
- the granular absorbent material contains activated carbon, fumed silica, fine perlite, zeolites, processed clays or combinations thereof.
- the adsorbent/absorbent will exhibit clumping or matting characteristics for best performance and be well de-dusted.
- the granular absorbent material preferably has a surface area per mass or volume ratio. In some embodiments, the granular absorbent material has a surface area per mass ratio in the range of 100-10,000 m 2 /g, 100-9,000 m 2 /g, 100-8,000 m 2 /g, 300-8,000 m 2 /g, 1,000-8,000 m 2 /g, 2,000-8,000 m 2 /g, 3,000-8,000 m 2 /g, 4,000-8,000 m 2 /g, 5,000-8,000 m 2 /g, 6,000-8,000 m 2 /g, 7,000-8,000 m 2 /g, 100-7,000 m 2 /g, 300-7,000 m 2 /g, 1,000- 7,000 m 2 /g, 2,000-7,000 m 2 /g, 3,000-7,000 m 2 /g, 4,000-7,000 m 2
- the granular absorbent material has a surface area per mass ratio up to 10,000 m 2 /g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 9,000 m 2 /g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 8,000 m 2 /g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 7,000 m 2 /g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 6,000 m 2 /g.
- the granular absorbent material has a surface area per mass ratio of 100 m 2 /g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 300 m 2 /g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 1,000 m 2 /g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 2,000 m 2 /g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 3,000 m 2 /g or greater.
- the granular absorbent material has a surface area per mass ratio of 4,000 m 2 /g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 5,000 m 2 /g or greater.
- the granular absorbent material has a surface area per mass ratio in the range of 1000-6,000 m 2 /g. [0027] In some embodiments, the granular absorbent material contains ceramic minerals.
- the granular absorbent material contains perlite and/or vermiculite.
- the granular absorbent material has a surface area per volume ratio in the range of 100-5,000 m 2 /ml, 300-5,000 m 2 /ml, 1,000-5,000 m 2 /ml, 2,000-5,000 m 2 /ml, 3,000-5,000 m 2 /ml, 4,000-5,000 m 2 /ml, 100-4,000 m 2 /ml, 300-4,000 m 2 /ml, 1,000-4,000 m 2 /ml, 2,000-54,000 m 2 /ml, 3,000-4,000 m 2 /ml, 100-3,000 m 2 /ml, 300-3,000 m 2 /ml, 1,000- 3,000 m 2 /ml, 2,000-3,000 m 2 /ml, 100-2,000 m 2 /ml, 300-2,000 m 2 /ml, or 1,000-2,000 m 2 /ml.
- the granular absorbent material has a surface area per volume ratio up to 5,000 m 2 /ml. In some embodiments, the granular absorbent material has a surface area per volume ratio up to 4,000 m 2 /ml. In some embodiments, the granular absorbent material has a surface area per volume ratio up to 3,000 m 2 /ml.
- the granular absorbent material has a surface area per volume ratio of 100 m 2 /ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio of 300 m 2 /ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio of 1,000 m 2 /ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio of 2,000 m 2 /ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio in the range of 1000-3,000 m 2 /ml.
- ceramics shall mean compounds of nonmetallic elements possessing in general hardness, compressive strength, elastic modulus, thermal expansion and density.
- Exemplary ceramics include, but are not limited to, materials used in pottery, bricks, tiles, cements and glass, barium titanate, strontium titanate, bismuth strontium calcium copper oxide, boron oxide, boron nitride, earthenware, ferrite, lead zirconate titanate, magnesium diboride, porcelain, sialon, silicon carbodie, silicon nitride, steatite, titanium carbide, uranium oxide, yttrium barium copper oxide, zinc oxide, zirconium dioxide, and partially stabilized zirconia.
- Ceramics may be oxides (aluminia, beryllia, ceria, zirconia), nonoxides (carbide, boride, nitride, silicide) or composite materials (combinations of oxides and onoxides).
- Perlite is a naturally occurring form of obsidian characterized by spherulites formed by cracking of volcanic glass during cooling. Perlite typically comprises a mix of silicon dioxide, aluminium oxide, sodium oxide, potassium oxide, iron oxide, magnesium oxide and calcium oxide. Potential substitutes for perlite include, but are not limited to, diatomite, expanded clay, shale, pumice, slag or vermiculite. Vermiculite is a naturally occurring hydrous phyllosilicate material, which is 2:1 clay. [0034] As used herein, the term “zeolite” shall mean any of a large group of minerals comprising hydrated aluminosilicates of sodium, potassium, calcium and barium.
- Zeolite can occur naturally, but is also artificially synthesized.
- exemplary zeolites include, but are not limited to, analcime, chabazite, clinoptilolite, heulandite, natrolite, phillipsite, and stilbite.
- activate carbon shall mean a form of carbon processed to have small, low-volume pores that increase the surface area available for adsorption or chemical reactions.
- a synonym for activate carbon is “activated charcoal.”
- cellulosic absorbents shall mean cellulose and cellulose derivatives that can provide structure, bulk, water-holding capacity and channeling of fluids over a wide dimensional range.
- fibrous absorbents refers to a fibrous structure with high void volume, a hydrophilic nature, and wet resiliency.
- fibrous absorbents include, but are not limited to, cotton fiber based absorbents, com fiber based absorbents and hemp based absorbents.
- the granular absorbent material constitutes 10-70% (w/w), 10-60% (w/w), 10-50% (w/w), 10-40% (w/w), 10-30% (w/w), 10-20% (w/w), 20-70% (w/w), 20-60% (w/w), 20-50% (w/w), 20-40% (w/w), 20-30% (w/w), 30-70% (w/w), 30-60% (w/w), 30-50% (w/w), 30-40% (w/w), 40-70% (w/w), 40-60% (w/w), 40-50% (w/w), 50-70% (w/w), 50-70% (w/w) or 60-70% (w/w) of the final product.
- the granular absorbent material constitutes 25-30% (w/w) of the final product. In some embodiments, the granular absorbent material constitutes about 27% (w/w) of the final product.
- the coating agent can be any biocide capable of forming a coating layer on the surface of the granular absorbent material of the present application.
- the coating agent contains one or more agents selected from the group consisting of silanes, siloxanes, aminopropyltrimethoxysilane, quaternary amines, fumed metal hydroxides, solutions of silver, solutions of copper and combinations thereof.
- the coating agent is a biocide that forms a surface bonded film on the granular absorbent material.
- the static surface bonded biocide film provides a long term inactivation or inhibition of pathogens in contact with the cleaning composition of the present invention, thus providing a long term assurance of the effectiveness of the cleaning effect.
- the coating agent is applied to the granular absorbent material by vapor deposition. In some embodiments, the vapor deposition is performed by thermal heating the coating agent and the granular absorbent. [0041] In some embodiments, the coating agent is applied to the granular absorbent material by pressure micro droplet spray.
- the coating agent is applied to the granular absorbent material by a fuming or fogging nozzle.
- the coating agent is applied to the granular absorbent material by a deposition technique commonly used for metal plating.
- biocide refers to any material that destroys, inactivates, eliminates, deters, inhibits the growth of, or otherwise render harmless and/or prevent damage or infection of a pathogen or a microorganism.
- biocide includes, but are not limited to, silanes, siloxanes, aminopropyltrimethoxysilane, quaternary amines, fumed metal hydroxides, silver and salts or solutions thereof, copper and salts or solutions thereof, formaldehyde; bronopol; chlorocresol; peracetic acid; chloroxylenol; biphenyl-2-ol; hexa-2,4-dienoic acid/scorbutic acid; glutaral; clorofen; 2-phenoxy ethanol; cetylpyridinium chloride; tosylchloramide sodium; sodium 2-biphenylate; phthalaldehyde; N-(3-aminopropyl)- N-dodecylpropan-l,3-diamine; troclosen sodium; sodium dichloroisocyanurate dihydrate; didecyldimethylammonium chloride; iodine; sodium hypochlorite; hydrogen peroxide; calcium hypo
- silanes refers chemical compounds with four substituents on silicon, including an organosilicon compound.
- exemplary silanes include, but are not limited to, trichlorosilane (SiHCh), tetramethylsilane (Si(CH3)4) and tetraethoxysilane (Si(OC 2 H 5 )4).
- siloxanes refers to chemical compounds that contain a functional group in organosilicon chemistry with the Si-O-Ai linkage.
- exemplary siloxanes include, but are not limited to, poly dimethylsiloxane or cyclomethicones.
- pathogen includes, but is not limited to, viruses, bacteria, yeast, protozoan, or other pathogenic microorganisms. Definitions and description of pathogens that may be eliminated, killed, inactivated or inhibited by administering the cleaning composition of the present application are described below. One of ordinary skill will understand that the described pathogens herein are not limiting.
- the biocide and/or the cleaning composition of the present application can address such critical pathogen families as norovirus, HIV, MRS A, C. Diff, hepatitis, ebola, Gl-related viruses of many sorts or targeted bioterror agents, amongst others defined and described below.
- Bacterial infections leading to gastroenteritis can be caused by Campylobacter, Escherichia coli, Salmonella, Shigella, Staphylococcus aureus, and Clostridum bacterial species.
- Protozoa infections leading to gastroenteritis can be a result of Giardia, Entamoeba, and Cryptosporidium species.
- bacteria shall mean members of a large group of unicellular microorganisms that have cell walls but lack organelles and an organized nucleus. Synonyms for bacteria include the terms “microorganisms”, “microbes”, “germs”, “bacilli”, “pathogens”, and “prokaryotes.” Exemplary bacteria include, but are not limited to Mycobacterium species, including M. tuberculosis,' Staphylococcus species, including S. epidermidis, S. aureus, and methicillin-resistant S. aureus,' Streptococcus species, including S. pneumoniae, S. pyogenes, S. mutans, S.
- Corynebacterium species including C. diphtheriae, C. ulcerans, C. pseudotuberculosis, C. pseudodiphtheriticum, C. urealyticum, C. hemolyticum, C. equi; Listeria monocytogenes, Nocardia asteroides, Bacteroides species, Actinomycetes species, Treponema pallidum, Leptospirosa species, Klebsiella pneumoniae; Proteus sp., including Proteus vulgaris,' Serratia species, Acinetobacter , Yersinia species, including Y. pestis and Y. pseudotuberculosis,' Francisella tularensis, Enterobacter species, Bacteriodes species, Legionella species, Borrelia burgdorferi, and the like.
- MRSA methicillin-resistant Staphylococcus aureus
- C. Diff shall mean a species of gram-positive sporeforming bacterium known as Clostridium difficile, or C. difficile, or C. diff or sometimes CDF/cdf Clostridium difficile infection (CDI) is a symptomatic infection caused by this bacteria which can cause C. difficile associated diarrhea or Clostridum difficile colitis.
- CDI Clostridium difficile infection
- fungi shall mean any member of the group of saprophytic and parasitic spore-producing eukaryotic typically filamentous organisms formerly classified as plants that lack chlorophyll and include molds, rusts, mildews, smuts, mushrooms, and yeasts.
- Exemplary fungi include, but are not limited to, Aspergillus species, Dermatophytes, Blastomyces derinatitidis , Candida species, including C. albicans and C.
- T. schoenleinii T. megninii, T. soudanense, T. equinum, T. erinacei, and T. verrucosum
- Mycoplasma genitalia Microsporum species, including M. audouini, M. ferrugineum, M. cants, M. nanum, M. distortum, M. gypseum, M. fulvum, and the like.
- protozoans shall mean any member of a diverse group of eukaryotes that are primarily unicellular, existing singly or aggregating into colonies, are usually nonphotosynthetic, and are often classified further into phyla according to their capacity for and means of motility, as by pseudopods, flagella, or cilia.
- Exemplary protozoans include, but are not limited to Plasmodium species, including P. falciparum, P. vivax, P. ovale, and P. malariae; Leishmania species, including L. major, L. tropica, L. donovani, L. infantum, L. chagasi, L. mexicana, L. panamensis, L. braziliensis and L. guyanensi; Cryptosporidium, Isospora belli, Toxoplasma gondii, Trichomonas vaginalis, and Cyclospora species.
- targeted bioterror agents includes, but is not limited to, anthrax (Bacillus anthracis), botulism (Clostridium botulinum toxin), plague (Yersinia pestis). smallpox (Variola virus), tularemia (Franciscella tularensis) and viral hemorrhagic fever (arenaviruses, bunyaviruses, filoviruses, and arenaviruses), or other CDC Category A Agents.
- Brucella species Clostrodium perfringens, Salmonella species, Escherichia coli, and Shigella species, Burkholderia mallei, Burkholderia pseudomallei, Chlamydia psittaci, Coxiella brunetii, Ricinus communis, Rickettsia prowazekii, Vibrio cholera, and Cryptosporidium parvum, and alphaviruses, e.g., Venezuelan equine encephalitis, eastern equine encephalitis, and western equine encephalitis viruses and other CDC Category B Agents. Emerging infectious disease infectious agents such as Nipah virus, hantavirus and other CDC Category C Agents.
- the coating agent is added in an amount that constitutes 0.1 to 10% (w/w), 0.1 to 5% (w/w), 0.1 to 2% (w/w), 0.1 to 1% (w/w), 0.1 to 0.5% (w/w), 0.3 to 10% (w/w), 0.3 to 5% (w/w), 0.3 to 2% (w/w), 0.3 to 1% (w/w), 1 to 10% (w/w), 1 to 5% (w/w), 1 to 2% (w/w), 3 to 10% (w/w) or 3 to 5% (w/w) of the final product.
- the coating agent is added in an amount that constitutes 0.5 to 3.5% (w/w) or 1 to 3% (w/w) of the final product. In some embodiments, the coating agent is added in an amount that constitutes about 2% (w/w) of the final product.
- the sanitation agent can be any agent having biocide activity and can be absorbed by the coated granular absorbent of the present application.
- the sanitation agent comprise an active substance designed to destroy, inhibit, reduce activity, inhibit grow or otherwise render harmless harmful organisms or toxic chemicals.
- the sanitation agent is a liquid phase agent.
- the sanitation agent is a liquid phase biocide.
- the sanitation agent is a liquid phase chemical that inactivates or removes toxic chemicals, such as chemo therapy drugs.
- the liquid phase biocide is added at an application site to provide chemical disinfection for immediate response.
- liquid phase biocide examples include, but are not limited to, chlorine bleach solutions, hydrogen peroxide solutions, peracetic acid, quaternary amine solutions, alcohol solutions, periodine solutions, dimethyl benzyl ammonium chloride, dimethyl ethybenzyl ammonium chloride and mixtures thereof.
- liquid phase chemicals that can be used to inactivate or remove toxic chemicals include, but are not limited to, anionic surfactants such as soap, sulfonates and sulfates. In some embodiments, large quantities of water is used to dilute the toxic chemicals.
- the sanitation agent is added in an amount that constitutes 0.1 to 10% (w/w), 0.1 to 3% (w/w), 0.1 to 1% (w/w), 0.1 to 0.3% (w/w), 0.3 to 10% (w/w), 0.3 to 3% (w/w), 0.3 to 1% (w/w), 1 to 10% (w/w), 1 to 3% (w/w) or 3 to 10% (w/w) of the final product.
- the sanitation agent comprises dimethyl benzyl ammonium chloride or dimethyl ethybenzyl ammonium chloride. In some embodiments, the sanitation agent comprises a mixture of dimethyl benzyl ammonium chloride or dimethyl ethybenzyl ammonium chloride. In some embodiments, the sanitation agent is a 1 : 1 mixture of dimethyl benzyl ammonium chloride or dimethyl ethybenzyl ammonium chloride.
- the sanitation agent is a quatanary amine and is added in an amount that constitutes 0.3 to 3% (w/w), 0.5 to 2% (w/w) or 0.5 to 1.5% (w/w) of the final product. In some embodiments, the sanitation agent is a quatanary amine and is added in an amount that constitutes about 1% (w/w) of the final product.
- CMC critical micelle concentration
- Anionic surfactants at low concentrations reduce the magnitude of the apparent capsid surface charge enough to induce particle aggregation for capsids with a net negative surface charge.
- concentration of charged surfactant As the concentration of charged surfactant is increased beyond its CMC, the micelles can solubilize capsid protein dimers and therefore disassemble the capsid structure.
- surfactants are efficient in disrupting the virus structure only above their CMC, this should be taken into account when formulating virus cleaning and disinfectant systems with surfactants.
- Surfactant micellization results in the ability of strong surfactants to disrupt interactions between virus capsid proteins and solubilize individual proteins or dimers.
- Virus particle disassembly by surfactant is likely to lead to complete loss of infectivity, which can also be severely disrupted by the dramatic apparent surface charge alteration and aggregation caused by ionic surfactant.
- Low concentrations of ionic surfactants (below CMC) are likely to disrupt the virus infectivity much less.
- anionic surfactants are used as a sanitation agent to destroy viruses.
- Typical anionic surfactants include soaps, sodium dodecylsulfate (SDS), alkylbenzene sulfonates, alkyl sulfonates, alkyl sulfonates, alkyl sulfates, salts of fluorinated fatty acids, silicones, fatty alcohol sulfates, polyoxyethylene fatty alcohol ether sulfates, a-olefin sulfonate, polyoxyethylene fatty alcohol phosphates ether, alkyl alcohol amide, alkyl sulfonic acid acetamide, alkyl succinate sulfonate salts, amino alcohol alkylbenzene sulfonates, naphthenates, alkylphenol sulfonate and polyoxyethylene monolaurate.
- SDS sodium dodecylsulfate
- alkylbenzene sulfonates alky
- SDS is used as a sanitation agent absorbed in the granular ceramic material.
- SDS sodium lauryl sulfate (SLS)
- chemical formula NaChLLSSCL IUPAC, 2014
- SDS possesses a zwitterionic form in aqueous solution with two distinct portions, polar and apolar, at opposite ends of a single molecule. The polar end is formed by a sulfate group while the opposite end, apolar, is composed by a long chain hydrocarbon, which may be linear, branched or aromatic according to the diluent solution.
- the chemical nature of SDS provides adequate ionic balance, solubilizing fats and oils, and the formation of microemulsions, hence it is suitable as an ingredient in cleaning products.
- SDS Sud contact of SDS with cells will cause physical and biochemical effects.
- SDS is able to undo the barrier capacity of the cellular membrane due to its effect on lipids.
- the effects of SDS depend on absolute concentrations and lipid/surfactant molar ratios.
- cell membranes lose their barrier capacity increasing permeability.
- equal or superior surfactant/lipid ratios cause cell lysis. If levels of surfactant (SDS) exceed cytolytic concentrations, the lamellar structure of the membrane is solubilized releasing proteins, lipoproteins and micelles, resulting in a complete cell lysis.
- SDS surfactant
- anionic surfactants are effective at breaking up the lipid envelope, and thereby ending viral infectivity.
- the Modifying Agent is added to the coated granular absorbent or the absorbed- and-coated granular absorbent in an amount to achieve desired physical characteristics (e.g., non-dusty and clump, ease of pick up, liquid loadability, etc.) in the final product.
- desired physical characteristics e.g., non-dusty and clump, ease of pick up, liquid loadability, etc.
- the modifying agent include, but are not limited to, thickening agents, gums, absorbent polymers, tackifiers, and combinations thereof.
- thickening agent may include any material known or otherwise effective in providing suspending, gelling, viscosifying, solidifying or thickening properties to the composition or which otherwise provide structure to the final product form.
- thickening agents may include gelling agents, polymeric or nonpolymeric agents, inorganic thickening agents, or viscosifying agents. The amount and type of the thickening agent may vary depending upon the desired characteristics of the final product.
- tackifier refers to polymeric adhesives which increase the tack, i.e., the inherent stickiness or self-adhesion, of the compositions so that after a short period of gentle pressure they adhere firmly to surfaces.
- suitable tackifiers comprise high-flexibility resins such as, but not limited to, homopolymers of alkyl(meth)acrylates, especially alkyl acrylates, such as poly(isobutyl acrylate) or poly(2- ethylhexyl acrylate), linear polyesters, as commonly used for coil coating, linear difunctional oligomers, curable with actinic radiation, with a number average molecular weight of more than 2000, in particular from 3000 to 4000, based on polycarbonatediol or polyester-diol, linear vinyl ether homopolymers or copolymers based on ethyl, propyl, isobutyl, butyl and/or 2-ethylhexyl vinyl ether, or nonreactive urethane urea oligomers, which are prepared from bis(4,4- isocyanatophenyl)methane, N,N-dimethylethanolamine or diols such as propanediol,
- the modifying agent comprises a high-molecular substance that absorbs liquids, preferably water, swells, and finally is converted to a viscous true or colloidal solution.
- the modifying agent comprises one or more silicone gums.
- silicone gum means a silicone polymer having a degree of polymerization sufficient to provide a silicone having a gum-like texture. In certain cases the silicone polymer forming the gum may be crosslinked.
- the modifying agent comprises a polymer.
- the polymers include, but is not limited to, natural and synthetic polymers such as polyacrylamide (ACAM) and carboxymethyl cellulose.
- the polymers of the present application includes, but are not limited to, polyacrylates such as sodium polyacrylates, and carboxymethyl cellulose.
- the modifying agent comprises one or more superabsorbent polymer.
- superabsorbent polymer is understood to mean hydrophilic polymer structure capable of absorbing water or saline solution at greater than 10g of pure water/saline per gram of dry-based material (> lOg/g). Examples of super-absorbent polymers include, but are not limited to, sodium polyacrylates and carboxymethyl cellulose.
- the one or more modifying agents further comprise one or more additives selected from the group comprising denaturing agents, colorant agents, odor correctors, and/or pH regulators.
- the one or more modifying agents are added in an amount that constitute 0.1 to 5% (w/w), 0.1 to 2% (w/w), 0.1 to 1% (w/w), 0.1 to 0.3% (w/w), 0.3 to 5% (w/w), 0.3 to 2% (w/w), 0.3 to 1% (w/w), 1 to 5% (w/w), 1 to 2% (w/w) or 2 to 5% (w/w) of the final product.
- the cleaning composition contains an granular absorbent material coated with a coating agent.
- the coating agent contains a biocide.
- the biocide comprises an agent selected from the group consisting of silanes, siloxanes, aminopropyltrimethoxysilane, quaternary amines, fumed metal hydroxides, silver and salts of silver, copper and salts of copper.
- the biocide forms a static film on the surface of the granular absorbent material.
- the granular absorbent material contains activated carbon, fumed silica, fine perlite, zeolites, processed clays or combinations thereof.
- the coating agent constitutes 0.1 to 5% (w/w), 0.1 to 2% (w/w), 0.1 to 1% (w/w), 0.1 to 0.3% (w/w), 0.3 to 5% (w/w), 0.3 to 2% (w/w), 0.3 to 1% (w/w), 1 to 5% (w/w), 1 to 2% (w/w) or 2 to 5% (w/w) of the cleaning composition.
- the granular absorbent material contains ceramic minerals. In some embodiments, the granular absorbent material contains perlite and/or vermiculite. In some embodiments, the granular absorbent material has a surface area per mass ratio in the range of 100-10,000 m 2 /g, 100-9,000 m 2 /g, 100-8,000 m 2 /g, 300-8,000 m 2 /g, 1,000-8,000 m 2 /g, 2,000-8,000 m 2 /g, 3,000-8,000 m 2 /g, 4,000-8,000 m 2 /g, 5,000-8,000 m 2 /g, 6,000-8,000 m 2 /g, 7,000-8,000 m 2 /g, 100-7,000 m 2 /g, 300-7,000 m 2 /g, 1,000-7,000 m 2 /g, 2,000-7,000 m 2 /g, 3,000- 7,000 m 2 /g, 4,000-7,000 m 2 /g, 5,000-7,000 m 2 /g, 5,000-7,000
- the granular absorbent material has a surface area per mass ratio up to 10,000 m 2 /g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 9,000 m 2 /g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 8,000 m 2 /g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 7,000 m 2 /g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 6,000 m 2 /g.
- the granular absorbent material has a surface area per mass ratio of 100 m 2 /g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 300 m 2 /g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 1,000 m 2 /g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 2,000 m 2 /g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 3,000 m 2 /g or greater.
- the granular absorbent material has a surface area per mass ratio of 4,000 m 2 /g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 5,000 m 2 /g or greater.
- the granular absorbent material has a surface area per mass ratio in the range of 1000-6,000 m 2 /g.
- the granular absorbent material has a surface area per volume ratio in the range of 100-5,000 m 2 /ml, 300-5,000 m 2 /ml, 1,000-5,000 m 2 /ml, 2,000-5,000 m 2 /ml, 3,000-5,000 m 2 /ml, 4,000-5,000 m 2 /ml, 100-4,000 m 2 /ml, 300-4,000 m 2 /ml, 1,000-4,000 m 2 /ml, 2,000-54,000 m 2 /ml, 3,000-4,000 m 2 /ml, 100-3,000 m 2 /ml, 300-3,000 m 2 /ml, 1,000- 3,000 m 2 /ml, 2,000-3,000 m 2 /ml, 100-2,000 m 2 /ml, 300-2,000 m 2 /ml, or 1,000-2,000 m 2 /ml.
- the granular absorbent material has a surface area per volume ratio up to 5,000 m 2 /ml. In some embodiments, the granular absorbent material has a surface area per volume ratio up to 4,000 m 2 /ml. In some embodiments, the granular absorbent material has a surface area per volume ratio up to 3,000 m 2 /ml.
- the granular absorbent material has a surface area per volume ratio of 100 m 2 /ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio of 300 m 2 /ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio of 1,000 m 2 /ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio of 2,000 m 2 /ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio in the range of 1000-3,000 m 2 /ml.
- the granular absorbent material constitutes 10-70% (w/w), 10-60% (w/w), 10-50% (w/w), 10-40% (w/w), 10-30% (w/w), 10-20% (w/w), 20-70% (w/w), 20-60% (w/w), 20-50% (w/w), 20-40% (w/w), 20-30% (w/w), 30-70% (w/w), 30-60% (w/w), 30-50% (w/w), 30-40% (w/w), 40-70% (w/w), 40-60% (w/w), 40-50% (w/w), 50-70% (w/w), 50-70% (w/w) or 60-70% (w/w) of the cleaning composition.
- the granular absorbent material constitutes 25-30% (w/w) of the final product. In some embodiments, the granular absorbent material constitutes about 27% (w/w) of the cleaning composition.
- the cleaning composition further comprises a sanitation agent absorbed in the coated granular absorbent material.
- a sanitation agent absorbed in the coated granular absorbent material. Examples of the sanitation agent have been described above.
- the sanitation agent comprise an active substance designed to destroy, inhibit, reduce activity, inhibit grow or otherwise render harmless harmful organisms or toxic chemicals.
- the sanitation agent is a liquid phase agent.
- the sanitation agent is a liquid phase biocide.
- the sanitation agent is a liquid phase chemical that inactivates toxic chemicals, such as chemo therapy drugs.
- liquid phase biocide examples include, but are not limited to, chlorine bleach solutions, hydrogen peroxide solutions, peracetic acid, quaternary amine solutions, periodine, alcohol solutions, dimethyl benzyl ammonium chloride, dimethyl ethybenzyl ammonium chloride and mixtures thereof.
- liquid phase chemicals that can be used to inactivate or remove toxic chemicals include, but are not limited to, anionic surfactants such as soap, sulfonates and sulfates. In some embodiments, large quantities of water is used to dilute the toxic chemicals.
- the sanitation agent constitutes 0.1 to 10% (w/w), 0.1 to 3% (w/w), 0.1 to 1% (w/w), 0.1 to 0.3% (w/w), 0.3 to 10% (w/w), 0.3 to 3% (w/w), 0.3 to 1% (w/w), 1 to 10% (w/w), 1 to 3% (w/w) or 3 to 10% (w/w) of the cleaning composition.
- the sanitation agent comprises dimethyl benzyl ammonium chloride or dimethyl ethybenzyl ammonium chloride. In some embodiments, the sanitation agent comprises a mixture of dimethyl benzyl ammonium chloride or dimethyl ethybenzyl ammonium chloride. In some embodiments, the sanitation agent is a 1 : 1 mixture of dimethyl benzyl ammonium chloride or dimethyl ethybenzyl ammonium chloride.
- the cleaning composition further comprises one or more modifying agent.
- the modifying agent comprises a thickening agent, a tackifier, a gum, an absorbent polymers or combinations thereof.
- the one or more modifying agents comprise a carboxymethyl cellulose (CMC)-derived polymer and/or a hierarchically porous carbons (HPC)-derived polymer.
- the one or more modifying agents further comprise one or more additives selected from the group comprising denaturing agents, colorant agents, odor correctors, and/or pH regulators.
- the one or more modifying agents constitute 0.1 to 5% (w/w), 0.1 to 2% (w/w), 0.1 to 1% (w/w), 0.1 to 0.3% (w/w), 0.3 to 5% (w/w), 0.3 to 2% (w/w), 0.3 to 1% (w/w), 1 to 5% (w/w), 1 to 2% (w/w) or 2 to 5% (w/w) of the cleaning composition.
- the cleaning composition has a liquid loading capability in the range of 10-50% by volume, 15-45% by volume, 20-40% by volume, 25-35% by volume, or 25-30% by volume. In other embodiments, the cleaning composition has a liquid loading capability of 100-400% by mass addition, 150-350% by mass addition, or 200-300% by mass addition. In some embodiments, the cleaning composition of the present application is capable of absorbing liquid at a liquid loading of 25-30% by volume or 200-300% by mass addition.
- the cleaning composition is specifically designed to kill or inactivate enveloped viruses, such as coronaviruses.
- the cleaning composition comprises ethyl alcohol, isopropyl alcohol, chlorine or hypochlorites, chlorine dioxide, sodium dichloroisocyanurate, and chloramine-T, formaldehyde, glutaraldehyde, hydrogen peroxide, iodophors, ortho-phthalaldehyde, peracetic acid, phenolics, quaternary ammonium compounds, or in conjunction with superoxidized water.
- Another aspect of the present application relates to a method of using the cleaning composition of the present application.
- the method comprises the steps of applying an effective amount of the cleaning composition of the present application to a surface in need of cleaning, and remove the cleaning composition after a period of time.
- the period of time is from 30 seconds to 30 minutes. In some embodiments, the period of time is from 1 to 30 minutes, from 1 to 20 minutes, from 1 to 10 minutes, from 2 to 30 minutes, from 2 to 20 minutes, from 2 to 10 minutes, from 5 to 30 minutes, from 5 to 20 minutes and from 5 to 10 minutes.
- the surface in need of cleaning comprises a biohazard spill.
- the biohazard spill is vomit, urine, blood, feces, and/or a chemo therapy drug.
- the surface in need of cleaning is a surface in a public area and needs to be treated to prevent or reduce cross contamination or infection.
- the term “public area” includes, but is not limited to, hospitals, doctors’ offices, urgent care facilities, nursing homes, prisons and related correction facilities, schools, buses, aircraft, airports, bars, restaurants, hotels, amusement parks, any large gathering institution facilities, veterinary facilities and drug research and development facilities.
- the public area is located in a hotel.
- the method further comprises the step of: washing the treated surface with a liquid or wiping the surface with a wiping material, such as paper tower or mops, after the removal of the cleaning composition.
- a wiping material such as paper tower or mops
- Another aspect of the present application relates to a method of disinfecting an affected area to prevent or reduce the distribution of pathogens such as viruses and bacteria.
- the method comprises the steps of apply an effective amount of the cleaning composition of the present application to the affected area and remove the cleaning composition after a period of time, wherein the cleaning composition contains a granular absorbent material coated with a static, surface bonded film of biocide selected from the group consisting of silanes, siloxanes, aminopropyltrimethoxysilane, quaternary amines, fumed metal hydroxides, silver and salts of silver, copper and salts of copper.
- a static, surface bonded film of biocide selected from the group consisting of silanes, siloxanes, aminopropyltrimethoxysilane, quaternary amines, fumed metal hydroxides, silver and salts of silver, copper and salts of copper.
- the cleaning composition further comprises a sanitation agent selected from the group consisting of chlorine bleach solutions, hydrogen peroxide solutions, per acetic acid, quaternary amine solutions and alcohol solutions.
- a sanitation agent selected from the group consisting of chlorine bleach solutions, hydrogen peroxide solutions, per acetic acid, quaternary amine solutions and alcohol solutions.
- the sanitation agent is added to the cleaning composition immediately prior to the application to the affected area.
- the cleaning composition of the present application is a multi-phase product that can be used to kill microbes through a number of different mechanisms.
- the composition is a doped granular ceramic disinfectant which combines a surface area static disinfectant or biocide coating with a chemical phase primary disinfectant or biocide absorbed in the ceramic particles.
- the term “disinfectant” describes the composition and formulations described herein for the elimination of pathogens from surfaces.
- the term "disinfect” shall mean the elimination of many or all pathogens on a surface to which disinfectant is administered.
- the cleaning composition of the present application is a surface area solid phase disinfectant that combines with a super absorbent polymer so that liquid loadings (e.g., 25-30% by volume/200-300% by mass addition) of available liquid can be added so as to impart chemical disinfection, to impart deodorizing chemicals or to impart a blanketing effect on the affected area so as to reduce the spread of microbe into the open air.
- liquid loadings e.g., 25-30% by volume/200-300% by mass addition
- the cleaning composition of the present application is a high surface area solid phase disinfectant with the addition of tackifiers, so that it lays on a bio hazard and forms a blanket which greatly reduces the release of airborne pathogens.
- the cleaning composition is designed to be spray able on surfaces that may be contaminated with a virus.
- the blend of a sprayable cleaning composition can depend on the dispensing form (e.g., hose or trigger spray) and according to the surface that has to be decontaminated.
- Surfaces likely to become contaminated with viruses include medical and veterinary areas that come into contact with blood, body fluids, or internal mucosae of humans and animals. In terms of risk of virus transmission, these are considered to be critical contacts or, when only mucosae are involved, semicritical. Environmental surfaces are designated as critical only if they are in areas where highly susceptible individuals are housed, e.g., neonatal intensive care units, bum units, operating suites, nursing care homes, etc.
- the surfaces which may be likely to carry contaminating viruses can be broadly categorized as nonporous inanimate, porous inanimate (e.g., linen), and animate (e.g., skin).
- nonporous inanimate surfaces can be divided into instruments used for medical and veterinary procedures which are soaked in disinfectant solution between use, and environmental surfaces and objects which are usually decontaminated by wiping with towels, etc.
- Such surface may include everything from egg shells to cement, but, in practice, stainless steel, plastics, ceramics, glass, and painted surfaces are the most likely to be treated with decontaminants regularly.
- the cleaning composition of the present application is used in a procedure specifically designed to kill or inactivate enveloped viruses, such as coronaviruses.
- kits can be used for cleaning up hazardous materials, such as vomit, urine, blood, feces, and/or a spill of chemo therapy drug, or disinfecting a surface.
- the kit contains the cleaning composition of the present application and instructions on how to use the cleaning composition.
- the kit further contains a copy of OSHA guidelines. In some embodiments, the kit further contains one or more of the following: biohazard bags, gloves, twist tie, antimicrobial hand wipe, germicidal wipe, scoop/scraper.
- the cleaning kit can be conveniently placed in locations within quick reach of all caregivers. For example; all patient and chemotherapy rooms, case & crash carts, emergency vehicles, cafeteria, environmental services closets, and within or near first aid kits, etc.
- EXAMPLE 1 TESTS OF THE VIRUCIDAL EFFECT OF THE CLEANING COMPOSITION OF THE PRESENT APPLICATION
- Viral stock 1:10 dilution, 1ml virus + 9ml serum free EMEM
- Flask 1 2ml virus + 8ml media b. Flask 2: 1.5ml virus + 8.5ml media c. Plate 1: virus + media in all 6 cells d. Plate 2
- this test is designed to validate virucidal effectiveness claims for a product to be registered as a virucide. It determines the potential of the test agent to disinfect hard, non-porous surfaces contaminated with NOROVIRUS. This test is designed to simulate consumer use, conforms to EPA Guidelines DIS/TSS-7, November 1981, and follows the general procedure outlined in the FR notice for another surrogate virus available onlinel and Virucidal Testing Format and Statistics Primer issued by EPA (March 2000).
- test agents Two lots of the test agents will be used to inactivate the challenge virus that has been dried on a sterile glass surface (two replicates for each batch/lot of the test agents). The test agent will be tested in a manner consistent with the label directions for use of the test agent or as specified by the Sponsor.
- Test control and reference substances supplied by the Sponsor (see last page).
- the test agent will be tested as supplied by the Sponsor unless directed otherwise.
- the Sponsor before the initiation of testing, must specify all operations performed on the test agent such as dilutions of the test agent, the diluent for the test agent, or specialized storage conditions.
- test agent must be tested for identity, strength, purity, stability and uniformity as applicable. All unused test agent will be retained for a period after completion of the test, then discarded in a manner that meets the approval of the safety officer.
- B. Materials can include, but are not limited to:
- CRFK Crandel Reese Feline Kidney
- BA American Type Culture Collection, Manassas, VA; ATCC CCL-94).
- CRFK cells will be grown in Cell Culture Media (Eagle’s Minimum Essential Media containing $5% Fetal Bovine Serum) containing Fetal Bovine Serum (FBS).
- the FCV will be grown by inoculating confluent cell monolayers, no more than 24-48 hours in age, using low multiplicity of infection (MOI). Briefly, a flask of host cells grown in cell culture media containing 10% fetal bovine serum (FBS) will be used. The percent FBS contained in the stock virus aliquot will be adjusted to yield a minimum of a 5% organic soil load.
- MOI multiplicity of infection
- CPE cytopathic effects
- Stock virus will be prepared by collecting the supernatant culture fluid from 75-100% infected culture cells. The supernatant will be removed, aliquoted, and stored in an ultra-low temperature freezer until the day of use. On the day of use an aliquot will be removed, thawed and refrigerated until use in the assay.
- TEST SYSTEM IDENTIFICATION All Petri dishes, dilution tube racks, and host-containing apparatus will be labeled with the following information: virus, host, test agent, and project number.
- FCV Feline calici virus
- the F-9 strain of Feline calici virus will be obtained from the American Type Culture Collection, Manassas, VA, (ATCC VR-782).
- FCV Feline calici virus
- the FCV will be grown by inoculating confluent cell monolayers, no more than 24-48 hours in age, using low multiplicity of infection (MOI). Briefly, a flask of host cells grown in cell culture media containing 10% fetal bovine serum (FBS) will be used. Cells will be washed three times with phosphate buffered saline (PBS) and inoculated with virus.
- FBS fetal bovine serum
- the cell monolayer will be washed once in Earle’s balanced salt solution (EBSS), re-fed with cell culture media and incubated.
- EBSS Earle’s balanced salt solution
- CPE cytopathic effects
- the CPE starts to develop in 1-2 days following inoculation, and will be harvested when more than ninety percent cytopathic effects (CPE) are observed.
- Postincubation the cells will be disrupted, with cell debris removed by centrifugation.
- Stock virus will be prepared by collecting the supernatant culture fluid from 75- 100% infected culture cells.
- the supernatant will be removed, aliquoted, and stored in an ultralow temperature freezer until the day of use. On the day of use an aliquot is removed, thawed and refrigerated until use in the assay.
- the percent FBS contained in the stock virus aliquot is adjusted to yield a minimum of a 5% organic soil load. If the Sponsor chooses a soil load greater than 5%, the percent FBS contained in the stock virus aliquot will be adjusted to yield the percent soil load requested.
- B. Carrier Preparation An aliquot of 0.2 ml stock virus will be spread uniformly over the bottoms of 100 X 15 mm sterile glass Petri dishes with a cell scraper. The virus will be air-dried at room temperature for 30-60 minutes (until visibly dry). The drying conditions (temperature and humidity) will be appropriate for the test virus to obtain maximum survival following drying. The actual drying time and temperature will be recorded. Two carriers will be prepared for each lot of test agent and plate recovery control. Additionally, one carrier per test agent lot will be prepared for the neutralizer effectiveness control using cell culture media in place of stock virus.
- Test agent preparation The test agent will be prepared and used according to the Sponsor’s directions or proposed label claims.
- test For each of two batches of test substance, two dried virus films will be exposed to 2.0 ml of the use dilution of the test substance, or to the amount of spray released under use conditions (spray products) for a specified exposure time and temperature. Post contact time, the test agent will be neutralized and the mixture will be scraped from the surface of the dish. This will be considered approximately one log 10 dilution.
- FCV virusspecific cytopathic effects
- Virus stock titer The challenge virus will be titered at the time of the test to determine the relative infectivity of the virus and to demonstrate the susceptibility of the host cells to support infection of FCV.
- the virus inoculum will be serial diluted tenfold in cell culture media. Selected dilutions will be inoculated into four wells per dilution and incubated under the same conditions as the test.
- Plate recovery control Two ml of cell culture media will be added to the dried virus. Post-contact time, the virus/cell culture mixture will be subjected to the identical neutralization procedure as the test agent. If columns are used, a portion of the virus/cell culture media/neutralizer mixture will be used for the column titer control (see below). This control will determine the relative loss in virus infectivity resulting from drying and neutralization alone. The results from the PRC will be compared with the test results to confirm recovery of at least four log 10 of infectious virus following drying and neutralization. Its titer will be used to compare with the titers of the test results to reach the acceptable test criteria (see below).
- Neutralizer effectiveness control (NEC). The neutralization procedure will be dependent upon the active ingredient present in the test agent and in the internal control test agent. For this control, each lot of the test agent will be processed exactly as the test procedure, but instead of the viral inoculum, cell culture media will be added. Post neutralization, the sample will be divided into three portions [two for cytotoxicity related controls (see below) and one for neutralizer effectiveness]. [0139] If columns are used, each sample will be passed through individual columns and the eluate will be serial diluted as appropriate in cell culture media. If columns are not used, the neutralizer effectiveness samples will be serial diluted tenfold in cell culture media.
- the diluted samples will be mixed with low titer virus, held for a period equivalent to contact time and assayed for viral infectivity and/or cytotoxicity (see below), in order to determine the dilution of test agent at which virucidal activity, if any, is retained. Then the selected dilutions will be used to inoculate host cells as described for the test procedure. Dilutions that show virucidal activity will not be considered in determining reduction of viral infectivity by the test agent.
- CT Cytotoxicity control
- Viral and cytotoxicity titers will be expressed as -log 10 of the 50 percent titration endpoint infectivity (TCID 50 ), respectively, as calculated by the method of Spearman Karber. st
- the cleaning composition of the present application is tested for effectiveness according to EPA standard operating procedures to measure the effectiveness of hard surface disinfectants against Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella choleraesuis , Mycobacterium bovis, Clostridium difficile, and viruses.
- the standard operating procedures are based on strict interpretations of AO AC International and ASTM International standard methods.
- the cleaning composition of the present application is tested as a germicidal spray product with testing for effectiveness against Staphylococcus aureus, Pseudomonas aeruginosa and Salmonella enterica (EPA Method ID: MB-06-08 dated 9/22/2014).
- Test cultures of the bacterium are prepared as follows: Defrost a single cryovial at room temperature and briefly vortex to mix. Add 10 pL of the thawed frozen stock (single use) to a tube containing 10 mL of culture medium (Synthetic broth is used for 5. aureus, P. aeruginosa and S. enterica. Nutrient broth may be used for P.
- aeruginosa.' Vortex, and incubate at 36 ⁇ 1°C for 24 ⁇ 2 h.
- One daily transfer is required prior to the inoculation of a final test culture. Daily cultures may be subcultured for up to 5 days; each daily culture may be used to generate a test culture. For S. aureus and S. enterica only, briefly vortex the 24 h cultures prior to transfer. For the final subculture transfer, inoculate a sufficient number of 20 * 150 mm tubes containing 10 mL growth medium (e.g., synthetic broth or nutrient broth) with 10 pL per tube of the 24 h culture then vortex to mix. Incubate 48-54 h at 36 ⁇ 1°C without shaking.
- 10 mL growth medium e.g., synthetic broth or nutrient broth
- Carrier inoculation is carried out as follows: Inoculate approximately 80 carriers; 60 carriers are required for testing, 6 for control carrier counts, and 1 for the viability control.
- For P. aeruginosa remove the pellicle from the broth either by decanting the liquid aseptically into a sterile tube, by gently aspirating the broth away from the pellicle using a pipette, or by vacuum removal. Avoid harvesting pellicle from the bottom of the tube. Transfer test culture after pellicle removal into sterile 25 * 150 mm test tubes (up to approximately 20 mL per tube) and visually inspect for pellicle fragments. Presence of pellicle in the final culture makes it unusable for testing.
- the final test culture may be diluted (e.g., one part culture plus one part sterile broth) prior to the addition of the OSL to the inoculum using the sterile culture medium used to generate the final test culture (e.g, synthetic broth).
- the diluted test culture for carrier inoculation within 30 min. Add appropriate amount of organic burden if required. Swirl to mix.
- Enumeration of viable bacteria from carriers is conducted as follows: Assay dried carriers in 2 sets of three carriers, one set immediately prior to conducting the efficacy test and one set immediately following the test. Randomly select 6 inoculated carriers for carrier count analysis prior to efficacy testing. Place each of the inoculated, dried carriers in a 38 x 100 mm culture tube or sterile 50 mL polypropylene conical tube containing 20 mL of letheen broth. Vortex immediately - 60 ⁇ 5 seconds for P. aeruginosa or 120 ⁇ 5 seconds for S. aureus and S. enterica.
- Disinfectant sample preparation is conducted as follows: For aerosol cans and trigger or pump sprayers, shake the can 25 times prior to use, unless otherwise specified by the manufacturer. Spray the test substance for 10-15 seconds prior to testing to ensure sprayer is operating correctly and test substance is dispensed properly.
- For concentrated test substances aseptically prepare the test substance use-dilution required for the test using appropriate sterile glassware or pipettes.
- For concentrated test substances use > 1.0 mL or 1.0 g of the test substance sample to prepare the final solution to be tested.
- the test procedure is conducted as follows: After the required carrier drying time, spray the slides sequentially for a specified time, distance, and number of pumps at timed intervals (typically 30 seconds) with the carriers in a horizontal position. Use a certified timer to time the spray interval. Spray the slide within ⁇ 5 seconds of the specified time for a contact time of 1-10 minutes or within ⁇ 3 seconds for contact times ⁇ 1 minute. After spraying, maintain the carriers in a horizontal position. Treated carriers must be kept undisturbed during the contact time. After the last slide of a set (typically 20 slides) has been sprayed with the disinfectant, and the exposure time is complete, sequentially transfer each slide into the primary subculture tube containing the appropriate neutralizer within the ⁇ 5 second time limit.
- timed intervals typically 30 seconds
- Results are recorded as follows: Gently shake each tube prior to recording results. Record results as + (growth) or 0 (no growth) as determined by presence or absence of turbidity. Confirm a minimum of three positive carrier sets per test. If there are less than three positive carriers, then confirm each carrier.
- the cleaning composition of the present application is tested against the parameters set by the EPA in the Series 810 — Product Performance Test Guidelines, specifically public health uses of disinfectants (OCSPP 810.2200 (EPA-HQ-OPPT-2009-0150-0029)).
- OCSPP 810.2200 EPA-HQ-OPPT-2009-0150-0029
- testing is conducted against Salmonella enterica (S. enterica), formerly designated as Salmonella choleraesuis , American Type Culture Collection (ATCC) 10708 for effectiveness against Gram-negative bacteria, or Staphylococcus aureus (S. aureus) (ATCC 6538) for effectiveness against Gram-positive bacteria.
- Three batches of the product are tested at the lower certified limit (LCL). For each batch, sixty carriers are used in the test.
- the performance standard for 5. aureus is 0-3 positive carriers out of sixty.
- the performance standard for 5. enterica is 0-1 positive carriers out of sixty. Contamination of one carrier (culture tube) is allowed per 60-carrier set; occurrence of more than one contaminated carrier invalidates the test results. For germicidal spray products, the product should kill the test microorganisms on 59 out of each set of 60 carriers/slides. Contamination of only one carrier (culture tube) is allowed per 60-carrier set; occurrence of more than one contaminated carrier invalidates the test results.
- testing is conducted against S. aureus (ATCC 6538) and Pseudomonas aeruginosa (ATCC 15442).
- ATCC 15442 For use against fungus, to demonstrate efficacy, testing is conducted against Trichophyton mentagrophytes (ATCC 9533).
- testing is conducted against Hepatitis B virus, Hepatitis C virus, and Norovirus, the Duck Hepatitis B virus, Bovine Viral Diarrhea virus, and Feline Calicivirus, respectively, which are considered acceptable surrogates for testing.
- Coronaviruses are enveloped viruses with a positive-sense single-stranded RNA genome and a nucleocapsid of helical symmetry. Coronavirus virions are generally considered to have on average diameters of 80-120 nm, but the size range can vary from 50 nm up to 200 nm. Characteristic surface spikes or peplomers, which appear club-like, pear-shaped, or petalshaped, project some 17-20 nm from the virion surface, having a thin base that swells to a width of about 10 nm at the distal extremity. In certain coronaviruses a second set of projections, 5- 10-nm long, forms an undergrowth beneath the major spikes.
- Coronavirus infections begin with the binding of virions to host cellular receptors. The infection culminates in the deposition of the nucleocapsid into the cytoplasm, where the viral genome becomes available for translation.
- the positive-sense genome which functions in effect as the first mRNA of viral infection, is translated into the enormous replicase polyprotein.
- the replicase then uses the genome as the template for the synthesis, via negativestrand intermediates, of both new viral genomes and a set of subgenomic mRNAs. The latter are translated into structural proteins and accessory proteins.
- the membrane-bound structural proteins, M, S, and E, are inserted into the ER, from where they transit to the endoplasmic reticulum-Golgi intermediate compartment (ERGIC).
- Nucleocapsids are formed from the encapsidation of progeny genomes by N protein, and these coalesce with the membrane-bound components, forming virions by budding into the ERGIC. Finally, progeny virions are exported from infected cells by transport to the plasma membrane in smooth-walled vesicles, or Golgi sacs, that remain to be more clearly defined.
- a fraction of S protein that has not been assembled into virions ultimately reaches the plasma membrane.
- S protein can cause the fusion of an infected cell with adjacent, uninfected cells, leading to the formation of large, multinucleate syncytia. This enables the spread of infection independent of the action of extracellular virus, thereby providing some measure of escape from immune surveillance.
- SARS-CoV-2 coronavirus coronavirus coronavirus
- SARS-CoV infects ciliated bronchial epithelial cells and type-II pneumocytes through angiotensin-converting enzyme 2 (ACE2) as receptor; mechanism of action for SARS-CoV-2 are still being determined.
- ACE2 angiotensin-converting enzyme 2
- SARS-CoV-2 has been detected in environmental samples from COVID-19 dedicated intensive care units (ICU) in hospitals. In rooms of COVID-19 patients, different levels of environmental contamination have been detected, ranging from 1 out of 13 to 13 out of 15 samples testing positive for SARS-CoV-2 prior to cleaning. One sample from an air exhaust outlet was positive indicating that virus particles may be displaced by air and deposited on surfaces, although no direct air samples tested positive. SARS-CoV-2 was also detected on objects such as the self-service printers used by patients to self-print the results of their exams, desktop keyboards and doorknobs. Virus was detected most commonly on gloves and, even rarely, on eye protection. The evidence shows the threat of contamination of SARS-CoV-2 in the environment of a COVID-19 patient, therefore reinforcing the need for decontamination of these environments.
- the cleaning composition described herein provides an effective solution. Decontamination Protocol
- Appropriate personal protective equipment is worn for cleaning up a body fluid spill. Gloves are worn during the cleaning and decontaminating procedures. To avoid the consequences of any splashing, the worker wears a face shield and gown. For large spills, overalls, gowns or aprons as well as boots or protective shoe covers are worn. Personal protective equipment is changed if tom or soiled, and is always removed before leaving the location of the spill, and then hands are washed.
- the cleaning composition is applied to spill - wait at least 60 seconds.
- Disposable towels are used to spread the cleaning composition to any areas not covered by initial application of the cleaning composition. Paper towels are disposed in plastic-lined waste receptacles
- the surface is sprayed or wiped thoroughly with the cleaning composition -the appropriate contact time is allowed to pass in accordance with the degree of severity of the spill (typically 1 - to 5 minutes).
- the cleaning composition is wiped up disposable paper towels. Paper towel are discarded as above. 7. Remove gloves and dispose in plastic-lined waste receptacle.
- the following active ingredients are some of those that are incorporated in the sanitation agent in the cleaning composition in combinations of one or more ingredients for use in decontamination of areas suspected of harboring SARS-CoV-2: quaternary ammonium; isopropanol; dodecylbenzenesulfonic acid; lactic acid; hydrogen peroxide; citric acid; chlorine dioxide; sodium hypochlorite; L-lactic acid; citric acid; thymol; peroxyacetic acid; potassium peroxymonosulfate; sodium chloride; thymol; ethanol; glutaraldehyde; phenols; sodium dischloroisocyanurate dehydrate; hypochlorous acid; silver; peroxy octanoic acid; sodium carbonate peroxyhydrate; sodium dichloro-S-triazinetrione; potassium peroxymonosulfate; ethyl alcohol; octanoic acid; glycolic acid; ammonium carbonate; ammonium bicarbonate.
Abstract
A method for formulating a cleaning composition contains the step of coating a granular absorbent material with a coating agent to produce a coated absorbent material and mixing the coated absorbent material with a sanitation agent, wherein the coated absorbent material absorbs the sanitation agent to form the cleaning composition. The resulting cleaning composition may be used for cleaning up pathogens or hazardous materials. The cleaning composition may also functions as a liquefiable dry cleaning powder for public areas in response to bodily fluid incidents. A coating method of a non-toxic bio static film on a high surface area solid is disclosed.
Description
TITLE
ANTI-VIRAL CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF
FIELD
[0001] The present application generally relates to a cleaning compositions and methods and, in particular, relates to a cleaning composition and method for cleaning up a virus, or other pathogens, on a surface, such as disinfecting, or removing viral particles from, a public area.
BACKGROUND
[0002] Typically, different types of disinfectants have been utilized as replacements to heat sterilization, radiation sterilization, or other less desirable techniques, in a variety of industries, including the pharmaceutical and medical industries, for some time. Disinfectants effectuate a safer, more cost effective and/or convenient means of eliminating potentially harmful germs, viruses, funguses and bacteria. However, the inherent strength of the chemical disinfectant has at times resulted in effectiveness and cost outweighing safety. Consequently, great care must be taken by the user regarding the nature of the use to which a chemical disinfectant is being put and there are stringent guidelines placed on all chemical disinfectant compositions.
SUMMARY
[0003] One aspect of the present application is directed to a method of formulating a cleaning composition to decontaminate surfaces contaminated by a virus, comprising the steps of: coating a granular absorbent material with a coating agent to produce a coated absorbent material; and mixing the coated absorbent material with a sanitation agent, wherein the coated absorbent material absorbs the sanitation agent to form the cleaning composition, wherein the sanitation agent comprises a surfactant. In certain embodiments, further comprising the step of: grinding an absorbent material to produce the granular absorbent material used in the coating step. In further embodiments, wherein the granular absorbent material is coated with a layer of surface bonded biocide by vapor deposition, pressure micro droplet spray or fuming or fogging nozzle. In additional embodiments, wherein the granular absorbent material is selected from the group consisting of ceramic minerals, zeolite, activated carbon, fumed silica, processed clays, cellulosic absorbents, fibrous absorbents and combinations thereof.
[0004] In certain embodiments, the granular absorbent material comprises ceramic minerals. In specific embodiments, the ceramic minerals comprise perlite and/or vermiculite. In some embodiments, the coating agent comprises a biocide. In particular embodiments, the coating agent forms a surface bonded film on the granular absorbent material.
[0005] In certain embodiments, the sanitation agent is an anionic surfactant.
[0006] Another aspect of the application is a method for prevention and/or decontamination of a surface from a virus, comprising: applying an effective amount of cleaning composition on said surface, wherein said cleaning composition comprises an granular absorbent material coated with a biocide; and a sanitation agent absorbed in said granular absorbent material, wherein said sanitation agent comprises a surfactant.
[0007] In certain embodiments, the virus is norovirus, HIV, rotavirus, adenovirus, astrovirus, coronavirus, hepatitis virus, ebola or norovirus, arenaviruses, bunyaviruses, filoviruses, arenaviruses, Nipah virus or hantavirus. In specific embodiments, the coronavirus is SARS-CoV-2.
[0008] Another aspect of the application is a cleaning composition for decontamination against viruses, comprising: a granular absorbent material coated with a biocide; and a sanitation agent absorbed in said granular absorbent material, wherein said sanitation agent comprises a surfactant. In particular embodiments, the granular absorbent material is selected from the group consisting of ceramic minerals, zeolite, activated carbon, fumed silica, processed clays, cellulosic absorbents, fibrous absorbents and combinations thereof. In certain embodiments, the granular absorbent material comprises ceramic minerals. In specific embodiments, the ceramic minerals comprise perlite and/or vermiculite. In some embodiments, the biocide forms a surface bonded film on the granular absorbent material.
[0009] Another aspect of the application is a sanitation method for decontamination against viruses, comprising the step of: applying an effective amount of a cleaning composition a cleaning composition for decontamination against viruses, comprising: an granular absorbent material coated with a biocide; and a sanitation agent absorbed in said granular absorbent material, wherein said sanitation agent comprises a surfactant to a surface in need of sanitation; and removing the cleaning composition after a period of time.
[0010] Another aspect of the application is a cleaning kit for decontaminating against viruses, comprising: a cleaning composition a cleaning composition for decontamination against viruses, comprising: an granular absorbent material coated with a biocide; and a sanitation agent absorbed in said granular absorbent material, wherein said sanitation agent comprises a surfactant, and instructions on how to use the cleaning composition. In certain embodiments, comprising one or more items selected from the group consisting of biohazard bags, gloves, twist tie, antimicrobial hand wipe, germicidal wipe, scoops and scrapers.
[0011] These and other aspects and embodiments of the present application will become better understood with reference to the following detailed description when considered in association with the accompanying drawings and claims.
DETAILED DESCRIPTION
[0012] The aspects of the application are described in conjunction with the exemplary embodiments, including methods, materials and examples, such description is non-limiting and the scope of the application is intended to encompass all equivalents, alternatives, and modifications, either generally known, or incorporated here. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. One of skill in the art will recognize many techniques and materials similar or equivalent to those described here, which could be used in the practice of the aspects and embodiments of the present application. The described aspects and embodiments of the application are not limited to the methods and materials described.
[0013] As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the content clearly dictates otherwise.
[0014] Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it is understood that the particular value forms another embodiment. It is further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that when a value is disclosed that "less than or equal to “the value,” greater than or equal to the value" and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “10” is disclosed the “less than or equal to 10” as well as “greater than or equal to 10” is also disclosed.
[0015] This application describes a novel, effective and low cost cleaning composition that can be used for rapid and safe clean-up of a surface contaminated by viruses through biohazard spills (vomit / urine / blood and feces) in hospitals, urgent care facilities, medical offices, nursing homes, prisons, schools and the hospitality industry. Viruses may have also contaminated the environment though coughing, sneezing, spitting, or other sources of respiratory droplets carrying viral load. References to pathogens herein should be understood to encompass viruses.
[0016] The cleaning composition of the present application is a multi-phase product that can be used to kill viruses through a number of different mechanisms by either disrupting the
viral proteins, or in certain instances the viral envelope. In one embodiment, the composition is a doped granular ceramic disinfectant which combines a surface area static disinfectant or biocide coating with a chemical phase primary disinfectant (e.g. surfactant) or biocide absorbed in the ceramic particles. The multi-phase product provides an effective means to decontaminate surfaces of viruses by acting as a delivery platform for a multi-pronged attack on the integrity of the virus. In some embodiments, the cleaning composition of the present application and the method of use thereof are designed to kill or inactivate enveloped viruses, such as coronaviruses.
[0017] Viruses may include viruses that can effect one or more of the nervous system, musculo-skeletal system, digestive system, hematological systems, immune systems, or respiratory systems. Examples of viruses include, but are not limited to, influenza viruses, herpesviruses, polioviruses, noroviruses, gastrointestinal tract-related (Gl-related) viruses, retroviruses, human immunodeficiency virus type 1 and type 2 (HIV-1 and HIV-2), human T- cell lymphotropic virus type I and type II (HTLV-I and HTLV-II), hepatitis A virus, hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis delta virus (HDV), hepatitis E virus (HEV), hepatitis G virus (HGV), parvovirus B19 virus, transfusion transmitted virus (TTV), Epstein- Barr virus, human cytomegalovirus type 1 (HCMV-1), human herpesvirus type 6 (HHV-6), human herpesvirus type 7 (HHV-7), human herpesvirus type 8 (HHV-8), influenza type A viruses, including subtypes H1N1 and H5N1, influenza type B viruses, human metapneumo virus, severe acute respiratory syndrome (SARS) coronavirus, SARS-CoV-2, Middle East respiratory syndrome (MERS), hantavirus, and RNA viruses from Arenaviridae (e.g., Lassa fever virus (LFV)), Pneumoviridae (e.g., human metapneumovirus), Filoviridae (e.g., Ebola virus (EBOV), Marburg virus (MBGV) and Zika virus); Bunyaviridae (e.g., Rift Valley fever virus (RVFV), Crimean-Congo hemorrhagic fever virus (CCHFV), and hantavirus); Flaviviridae (West Nile virus (WNV), Dengue fever virus (DENV), yellow fever virus (YFV), GB virus C (GBV-C; formerly known as hepatitis G virus (HGV)); Rotaviridae (e.g., rotavirus), human T-cell lymphotropic virus (HTLV) type I and type II (HTLV-I and HTLV-II), parvovirus B19 virus, transfusion transmitted virus (TTV); measles virus; rotaviruses, including Types A, B, C, D, and E; human papilloma virus (HPV) and its many serotypes; and other miscellaneous RNA viruses.
[0018] Examples of microbes caused causing gastroenteritis in man and animals include, viruses, bacteria, parasites and fungus. Viruses cause ~7-% of infectious diarrhea. Viral infections causing gastroenteritis can be attributed to rotavirus, adenovirus, norovirus, astrovirus, and coronavirus.
Enveloped Viruses
[0019] Enveloped viruses are usually inactivated by effective surface cleaning and disinfection. Enveloped viruses possess an envelope composed of a lipid layer (fat-like substance that is water insoluble) that forms an outer coating. The virus envelope is required for attachment of the virus to a target cell. The lipid layers in cellular membranes are impermeable to most polar or charged solutes but are permeable to apolar compounds, such as the lipids making up a viral envelope. Individual enveloped viruses have differing modes of transmission; however, typical routes of transmission are via indirect or direct bodily contact with infectious virus particles, such as by inhalation or contact with respiratory droplets carrying a viral load.
[0020] It is generally recognized that enveloped viruses are more readily inactivated by most chemical disinfectants than are nonenveloped viruses. Although the mechanisms of virus inactivation by chemicals is poorly understood, lipophilic disinfectants and chaotropic agents should have little difficulty in breaching a normal lipid bilayer. Thus, it is likely that the infectivity of enveloped viruses could be destroyed with little or no direct damage to the protein or nucleic acid of the virus. However, it is not known how much damage must be done to the virus envelope before virus infection is prevented. At high surfactant concentrations, damage to the proteins and nucleic acids of the virion is also likely.
Method of Making
[0021] One aspect of the present application is directed to a method of making a cleaning composition. The method comprises the steps of coating a granular absorbent material with a coating agent to produce a coated absorbent material; and mixing the coated absorbent material with a sanitation agent, wherein the coated absorbent material absorbs the sanitation agent to form a coated and absorbed absorbent material. In some embodiments, the method further comprises the step of grinding an absorbent material to produce the granular absorbent material used in the coating step. In other embodiments, the method further comprises the step of adding one or more modifying agent to the coated and absorbed absorbent material in amounts sufficient to achieve desired physical characteristics (e.g, non-dusty and clump, ease of pick up, liquid loading capacity, etc.).
[0022] The cleaning composition may be used to eradicate, eliminate, inactivate, inhibit the activity of, or reduce the amount of pathogens on a surface. The cleaning composition is especially for the clean-up of biohazard spills, such as vomit, urine, blood and feces in hospitals, urgent care facilities, medical offices, nursing homes, prisons, schools and the hospitality industry. The cleaning composition of the present application is also ideally suited for clean-up of common, highly hazardous spills in these environments, such as spills of chemotherapy drugs.
The Granular Absorbent Material
[0023] The granular absorbent material can be any solid material with desired surface area, granulation, and absorbent characteristics. As used herein, the term “absorbent” or “adsorbent” is understood to mean a material that is capable of imbibing and holding onto aqueous fluids. Suitable granular absorbent material include, but are not limited to, expanded and optimized ceramic minerals such perlite and vermiculite, zeolite, activated carbon, cellulosic absorbents and fibrous absorbents. In some embodiments, the granular absorbent material contains activated carbon, fumed silica, fine perlite, zeolites, processed clays or combinations thereof. The adsorbent/absorbent will exhibit clumping or matting characteristics for best performance and be well de-dusted. The granular absorbent material preferably has a surface area per mass or volume ratio. In some embodiments, the granular absorbent material has a surface area per mass ratio in the range of 100-10,000 m2/g, 100-9,000 m2/g, 100-8,000 m2/g, 300-8,000 m2/g, 1,000-8,000 m2/g, 2,000-8,000 m2/g, 3,000-8,000 m2/g, 4,000-8,000 m2/g, 5,000-8,000 m2/g, 6,000-8,000 m2/g, 7,000-8,000 m2/g, 100-7,000 m2/g, 300-7,000 m2/g, 1,000- 7,000 m2/g, 2,000-7,000 m2/g, 3,000-7,000 m2/g, 4,000-7,000 m2/g, 5,000-7,000 m2/g, 6,000- 7,000 m2/g, 100-6,000 m2/g, 300-6,000 m2/g, 1,000-6,000 m2/g, 2,000-6,000 m2/g, 3,000-6,000 m2/g, 4,000-6,000 m2/g, 5,000-6,000 m2/g, 100-4,000 m2/g, 300-4,000 m2/g, 1,000-4,000 m2/g, 2,000-4,000 m2/g, 3,000-4,000 m2/g, 100-3,000 m2/g, 300-3,000 m2/g, 1,000-3,000 m2/g, 2,000- 3,000 m2/g, 100-2,000 m2/g, 300-2,000 m2/g, or 1,000-2,000 m2/g.
[0024] In some embodiments, the granular absorbent material has a surface area per mass ratio up to 10,000 m2/g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 9,000 m2/g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 8,000 m2/g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 7,000 m2/g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 6,000 m2/g.
[0025] In some embodiments, the granular absorbent material has a surface area per mass ratio of 100 m2/g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 300 m2/g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 1,000 m2/g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 2,000 m2/g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 3,000 m2/g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 4,000 m2/g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 5,000 m2/g or greater.
[0026] In some embodiments, the granular absorbent material has a surface area per mass ratio in the range of 1000-6,000 m2/g.
[0027] In some embodiments, the granular absorbent material contains ceramic minerals.
[0028] In some embodiments, the granular absorbent material contains perlite and/or vermiculite.
[0029] In some embodiments, the granular absorbent material has a surface area per volume ratio in the range of 100-5,000 m2/ml, 300-5,000 m2/ml, 1,000-5,000 m2/ml, 2,000-5,000 m2/ml, 3,000-5,000 m2/ml, 4,000-5,000 m2/ml, 100-4,000 m2/ml, 300-4,000 m2/ml, 1,000-4,000 m2/ml, 2,000-54,000 m2/ml, 3,000-4,000 m2/ml, 100-3,000 m2/ml, 300-3,000 m2/ml, 1,000- 3,000 m2/ml, 2,000-3,000 m2/ml, 100-2,000 m2/ml, 300-2,000 m2/ml, or 1,000-2,000 m2/ml.
[0030] In some embodiments, the granular absorbent material has a surface area per volume ratio up to 5,000 m2/ml. In some embodiments, the granular absorbent material has a surface area per volume ratio up to 4,000 m2/ml. In some embodiments, the granular absorbent material has a surface area per volume ratio up to 3,000 m2/ml.
[0031] In some embodiments, the granular absorbent material has a surface area per volume ratio of 100 m2/ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio of 300 m2/ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio of 1,000 m2/ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio of 2,000 m2/ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio in the range of 1000-3,000 m2/ml.
[0032] As used herein, the term “ceramics” shall mean compounds of nonmetallic elements possessing in general hardness, compressive strength, elastic modulus, thermal expansion and density. Exemplary ceramics include, but are not limited to, materials used in pottery, bricks, tiles, cements and glass, barium titanate, strontium titanate, bismuth strontium calcium copper oxide, boron oxide, boron nitride, earthenware, ferrite, lead zirconate titanate, magnesium diboride, porcelain, sialon, silicon carbodie, silicon nitride, steatite, titanium carbide, uranium oxide, yttrium barium copper oxide, zinc oxide, zirconium dioxide, and partially stabilized zirconia. Ceramics may be oxides (aluminia, beryllia, ceria, zirconia), nonoxides (carbide, boride, nitride, silicide) or composite materials (combinations of oxides and onoxides).
[0033] Perlite is a naturally occurring form of obsidian characterized by spherulites formed by cracking of volcanic glass during cooling. Perlite typically comprises a mix of silicon dioxide, aluminium oxide, sodium oxide, potassium oxide, iron oxide, magnesium oxide and calcium oxide. Potential substitutes for perlite include, but are not limited to, diatomite, expanded clay, shale, pumice, slag or vermiculite. Vermiculite is a naturally occurring hydrous phyllosilicate material, which is 2:1 clay.
[0034] As used herein, the term “zeolite” shall mean any of a large group of minerals comprising hydrated aluminosilicates of sodium, potassium, calcium and barium. Zeolite can occur naturally, but is also artificially synthesized. Exemplary zeolites include, but are not limited to, analcime, chabazite, clinoptilolite, heulandite, natrolite, phillipsite, and stilbite.
[0035] As used herein, the term “activated carbon” shall mean a form of carbon processed to have small, low-volume pores that increase the surface area available for adsorption or chemical reactions. A synonym for activate carbon is “activated charcoal.”
[0036] As used herein, the term “cellulosic absorbents” shall mean cellulose and cellulose derivatives that can provide structure, bulk, water-holding capacity and channeling of fluids over a wide dimensional range.
[0037] As used herein, the term “fibrous absorbents” refers to a fibrous structure with high void volume, a hydrophilic nature, and wet resiliency. Examples of fibrous absorbents include, but are not limited to, cotton fiber based absorbents, com fiber based absorbents and hemp based absorbents.
[0038] In some embodiments, the granular absorbent material constitutes 10-70% (w/w), 10-60% (w/w), 10-50% (w/w), 10-40% (w/w), 10-30% (w/w), 10-20% (w/w), 20-70% (w/w), 20-60% (w/w), 20-50% (w/w), 20-40% (w/w), 20-30% (w/w), 30-70% (w/w), 30-60% (w/w), 30-50% (w/w), 30-40% (w/w), 40-70% (w/w), 40-60% (w/w), 40-50% (w/w), 50-70% (w/w), 50-70% (w/w) or 60-70% (w/w) of the final product. In some embodiments, the granular absorbent material constitutes 25-30% (w/w) of the final product. In some embodiments, the granular absorbent material constitutes about 27% (w/w) of the final product.
The Coating Agent
[0039] The coating agent can be any biocide capable of forming a coating layer on the surface of the granular absorbent material of the present application. In some embodiments, the coating agent contains one or more agents selected from the group consisting of silanes, siloxanes, aminopropyltrimethoxysilane, quaternary amines, fumed metal hydroxides, solutions of silver, solutions of copper and combinations thereof.
[0040] In some embodiments, the coating agent is a biocide that forms a surface bonded film on the granular absorbent material. The static surface bonded biocide film provides a long term inactivation or inhibition of pathogens in contact with the cleaning composition of the present invention, thus providing a long term assurance of the effectiveness of the cleaning effect. In some embodiments, the coating agent is applied to the granular absorbent material by vapor deposition. In some embodiments, the vapor deposition is performed by thermal heating the coating agent and the granular absorbent.
[0041] In some embodiments, the coating agent is applied to the granular absorbent material by pressure micro droplet spray.
[0042] In some embodiments, the coating agent is applied to the granular absorbent material by a fuming or fogging nozzle.
[0043] In some embodiments, the coating agent is applied to the granular absorbent material by a deposition technique commonly used for metal plating.
[0044] As used herein, the term “biocide” refers to any material that destroys, inactivates, eliminates, deters, inhibits the growth of, or otherwise render harmless and/or prevent damage or infection of a pathogen or a microorganism. Examples of biocide includes, but are not limited to, silanes, siloxanes, aminopropyltrimethoxysilane, quaternary amines, fumed metal hydroxides, silver and salts or solutions thereof, copper and salts or solutions thereof, formaldehyde; bronopol; chlorocresol; peracetic acid; chloroxylenol; biphenyl-2-ol; hexa-2,4-dienoic acid/scorbutic acid; glutaral; clorofen; 2-phenoxy ethanol; cetylpyridinium chloride; tosylchloramide sodium; sodium 2-biphenylate; phthalaldehyde; N-(3-aminopropyl)- N-dodecylpropan-l,3-diamine; troclosen sodium; sodium dichloroisocyanurate dihydrate; didecyldimethylammonium chloride; iodine; sodium hypochlorite; hydrogen peroxide; calcium hypochlorite; silver chloride; lignin; 2,2-dibromo-2-cyanoacetamide; sodium p-chloro-m- cresolate; d-gluconic acid compound with N,N"-bis(4-chlorophenyl)-3, 12-diimino-2, 4, 11,13- tetraazatetradecanediamidine (2:1); potassium (E,E)-hexa-2,4-dienoate; quaternary ammonium compounds, benzy 1-C 12-18-alky Idimethy 1-chlorides; benzy 1-C 12-16-alky Idimethy 1-chlorides; di-C8-10-alkyldimethyl-chlorides; pentapotassium bis(peroxymonosulfate)-bis(sulfate); benzyl- C12- 14-alky Idimethy 1-chlorides; Cl 2- 14-alkyl[(ethylphenyl)methyl]dimethy 1-chlorides; [2-[[2- [(2-carboxy ethyl)(2-hy droxy ethyl)-amino] ethyl] amino] -2-oxoethyl] -coco alkyldimethylhydroxides, internal salts; reaction products from: glutamic acid and N — (C 12- 14-alky 1)- propylenediamine; 6-(phthalimido)peroxyhexanoic acid; silver sodium hydrogen zirconium phosphate; poly(hexamethylendiamineguanidinium chloride); polyhexamethylene biguanide; oligo(2-(2-ethoxy)ethoxyethylguanidinium chloride) polymer; amines, n-C10-16- alkyltrimethylene di-, reaction products from chloroacetic acid; quaternary ammonium iodides; benzylalkyldimethyl(alkyl from C8-C22, saturated and unsaturated, and tallow alkyl, coco alkyl and soya alkyl), chlorides, bromides or hydroxi des)/BKC; dialkyldimethyl(alkyl from C6-C18, saturated and unsaturated, and tallow alkyl, coco alkyl and soya alkyl) chlorides, bromides or methylsulfates)/DDAC; 2-butanone, peroxide; boric acid; disodium octaborate tetrahydrate; triclosan; melaleuca altemifolia, extract/ Australian tea tree oil; sulfur dioxide; sodium hydrogen sulfite; disodium disulfite; sodium sulfite; potassium sulfite; dipotassium disulfite; l-[[2-(2,4-di- chlorophenyl)-4-propyl-l,3-dioxolan-2-yl]methyl]-lH-l,2,4-triazol/propiconazole; triclocarban;
dodecylguanidine monohydrochloride; silver zinc aluminum borophosphate glass/glass oxide, silver and zinc-containing; aluminum sodium silicate silver zinc complex/silver-zinc zeolite plant protection agents; sodium benzoate; disodium-tetraborate, anhydrous; mixture of cis and trans p-menthan-3,8-diol/citriodiol; mecetronium ethylsulfate; amines, C10-16-alkyldimethyl-, N-oxides; calcium dihexa-2,4-dienoate; sodium hydrogen carbonate; benzoxonium chloride; benzethonium chloride; tetradonium bromide; polyvinylpyrrolidone-iodine; silver nitrate; N,N'- (decan- 1 , 10-diy Idi- 1 (4H)-pyridy 1-4-y liden)bis(octy lammonium)di chloride; 2,4,8, 10-tetra(tert- buty l)-6-hy droxy- 12H-dibenzo [d,g] [1,3,2] dioxaphosphocin-6-oxide, sodium-salt.
[0045] As used herein, the term “silanes” refers chemical compounds with four substituents on silicon, including an organosilicon compound. Exemplary silanes include, but are not limited to, trichlorosilane (SiHCh), tetramethylsilane (Si(CH3)4) and tetraethoxysilane (Si(OC2H5)4).
[0046] As used herein, the term “siloxanes” refers to chemical compounds that contain a functional group in organosilicon chemistry with the Si-O-Ai linkage. Exemplary siloxanes include, but are not limited to, poly dimethylsiloxane or cyclomethicones.
[0047] As used herein, the term “pathogen” includes, but is not limited to, viruses, bacteria, yeast, protozoan, or other pathogenic microorganisms. Definitions and description of pathogens that may be eliminated, killed, inactivated or inhibited by administering the cleaning composition of the present application are described below. One of ordinary skill will understand that the described pathogens herein are not limiting. In some embodiments, the biocide and/or the cleaning composition of the present application can address such critical pathogen families as norovirus, HIV, MRS A, C. Diff, hepatitis, ebola, Gl-related viruses of many sorts or targeted bioterror agents, amongst others defined and described below.
[0048] Bacterial infections leading to gastroenteritis can be caused by Campylobacter, Escherichia coli, Salmonella, Shigella, Staphylococcus aureus, and Clostridum bacterial species. Protozoa infections leading to gastroenteritis can be a result of Giardia, Entamoeba, and Cryptosporidium species.
[0049] As used herein, the term “bacteria” shall mean members of a large group of unicellular microorganisms that have cell walls but lack organelles and an organized nucleus. Synonyms for bacteria include the terms “microorganisms”, “microbes”, “germs”, “bacilli”, “pathogens”, and “prokaryotes.” Exemplary bacteria include, but are not limited to Mycobacterium species, including M. tuberculosis,' Staphylococcus species, including S. epidermidis, S. aureus, and methicillin-resistant S. aureus,' Streptococcus species, including S. pneumoniae, S. pyogenes, S. mutans, S. agalactiae, S. equi, S. canis, S. bovis, S. equinus, S. anginosus, 5. sanguis, S. salivarius, S. mitis,' other pathogenic Streptococcal species, including
Enterococcus species, such as E. faecalis and E. faecium; Haemophilus influenzae, Pseudomonas species, including /*, aeruginosa, P. pseudomallei, and/*, mallei,' Salmonella species, including S. enterocolitis, S. typhimurium, S. enteritidis, S. bongori, and S. choleraesuis,' Shigella species, including S. flexneri, S. sonnei, S. dysenteriae, and S. boydii,' Brucella species, including B. melitensis, B. suis, B. abortus, and B. pertussis,' Neisseria species, including N. meningitidis and N. gonorrhoeae; Escherichia coli, including enterotoxigenic E. coli (ETEC); Vibrio cholerae, Helicobacter pylori, Chlamydia trachomatis, Clostridium difficile, Cryptococcus neoformans, Moraxella species, including M. catarrhalis, Campylobacter species, including C. jejuni,' Corynebacterium species, including C. diphtheriae, C. ulcerans, C. pseudotuberculosis, C. pseudodiphtheriticum, C. urealyticum, C. hemolyticum, C. equi; Listeria monocytogenes, Nocardia asteroides, Bacteroides species, Actinomycetes species, Treponema pallidum, Leptospirosa species, Klebsiella pneumoniae; Proteus sp., including Proteus vulgaris,' Serratia species, Acinetobacter , Yersinia species, including Y. pestis and Y. pseudotuberculosis,' Francisella tularensis, Enterobacter species, Bacteriodes species, Legionella species, Borrelia burgdorferi, and the like.
[0050] As used herein, the term “MRSA” shall mean the gram-positive bacterium methicillin-resistant Staphylococcus aureus (MRSA). The term MRSA encompasses any strain of S. aureus that has developed, through horizontal gene transfer and natural selection, multiple drug resistance to beta-lactam antibiotics.
[0051] As used herein, the term “C. Diff.” shall mean a species of gram-positive sporeforming bacterium known as Clostridium difficile, or C. difficile, or C. diff or sometimes CDF/cdf Clostridium difficile infection (CDI) is a symptomatic infection caused by this bacteria which can cause C. difficile associated diarrhea or Clostridum difficile colitis.
[0052] As used herein, the term “fungi” shall mean any member of the group of saprophytic and parasitic spore-producing eukaryotic typically filamentous organisms formerly classified as plants that lack chlorophyll and include molds, rusts, mildews, smuts, mushrooms, and yeasts. Exemplary fungi include, but are not limited to, Aspergillus species, Dermatophytes, Blastomyces derinatitidis , Candida species, including C. albicans and C. krusei,' Maias sezia furfur, Exophiala werneckii, Piedraia hortai, Trichosporon beigelii, Pseudallescheria boydii, Pneumocystis jiroveci, Madurella grisea, Histoplasma capsulatum, Sporothrix schenckii, Histoplasma capsulatum, Tinea species, including T. versicolor, T. pedis T. unguium, T. cruris, T. capitus, T. corporis, T. barbae; Trichophyton species, including T. rubrum, T. inter digitale, T. tonsurans, T. violaceum, T. yaoundei, T. schoenleinii, T. megninii, T. soudanense, T. equinum, T. erinacei, and T. verrucosum; Mycoplasma genitalia; Microsporum species, including M.
audouini, M. ferrugineum, M. cants, M. nanum, M. distortum, M. gypseum, M. fulvum, and the like.
[0053] As used herein, the term “protozoan” shall mean any member of a diverse group of eukaryotes that are primarily unicellular, existing singly or aggregating into colonies, are usually nonphotosynthetic, and are often classified further into phyla according to their capacity for and means of motility, as by pseudopods, flagella, or cilia. Exemplary protozoans include, but are not limited to Plasmodium species, including P. falciparum, P. vivax, P. ovale, and P. malariae; Leishmania species, including L. major, L. tropica, L. donovani, L. infantum, L. chagasi, L. mexicana, L. panamensis, L. braziliensis and L. guyanensi; Cryptosporidium, Isospora belli, Toxoplasma gondii, Trichomonas vaginalis, and Cyclospora species.
[0054] As used herein, the term “targeted bioterror agents” includes, but is not limited to, anthrax (Bacillus anthracis), botulism (Clostridium botulinum toxin), plague (Yersinia pestis). smallpox (Variola virus), tularemia (Franciscella tularensis) and viral hemorrhagic fever (arenaviruses, bunyaviruses, filoviruses, and arenaviruses), or other CDC Category A Agents. Brucella species, Clostrodium perfringens, Salmonella species, Escherichia coli, and Shigella species, Burkholderia mallei, Burkholderia pseudomallei, Chlamydia psittaci, Coxiella brunetii, Ricinus communis, Rickettsia prowazekii, Vibrio cholera, and Cryptosporidium parvum, and alphaviruses, e.g., Venezuelan equine encephalitis, eastern equine encephalitis, and western equine encephalitis viruses and other CDC Category B Agents. Emerging infectious disease infectious agents such as Nipah virus, hantavirus and other CDC Category C Agents.
[0055] In some embodiments, the coating agent is added in an amount that constitutes 0.1 to 10% (w/w), 0.1 to 5% (w/w), 0.1 to 2% (w/w), 0.1 to 1% (w/w), 0.1 to 0.5% (w/w), 0.3 to 10% (w/w), 0.3 to 5% (w/w), 0.3 to 2% (w/w), 0.3 to 1% (w/w), 1 to 10% (w/w), 1 to 5% (w/w), 1 to 2% (w/w), 3 to 10% (w/w) or 3 to 5% (w/w) of the final product.
[0056] In some embodiments, the coating agent is added in an amount that constitutes 0.5 to 3.5% (w/w) or 1 to 3% (w/w) of the final product. In some embodiments, the coating agent is added in an amount that constitutes about 2% (w/w) of the final product.
The Sanitation Agent
[0057] The sanitation agent can be any agent having biocide activity and can be absorbed by the coated granular absorbent of the present application. The sanitation agent comprise an active substance designed to destroy, inhibit, reduce activity, inhibit grow or otherwise render harmless harmful organisms or toxic chemicals. In some embodiments, the sanitation agent is a liquid phase agent. In some embodiment, the sanitation agent is a liquid phase biocide. In some embodiment, the sanitation agent is a liquid phase chemical that inactivates or removes toxic chemicals, such as chemo therapy drugs. In some embodiments, the
liquid phase biocide is added at an application site to provide chemical disinfection for immediate response.
[0058] Examples of liquid phase biocide include, but are not limited to, chlorine bleach solutions, hydrogen peroxide solutions, peracetic acid, quaternary amine solutions, alcohol solutions, periodine solutions, dimethyl benzyl ammonium chloride, dimethyl ethybenzyl ammonium chloride and mixtures thereof.
[0059] Examples of liquid phase chemicals that can be used to inactivate or remove toxic chemicals include, but are not limited to, anionic surfactants such as soap, sulfonates and sulfates. In some embodiments, large quantities of water is used to dilute the toxic chemicals.
[0060] In some embodiments, the sanitation agent is added in an amount that constitutes 0.1 to 10% (w/w), 0.1 to 3% (w/w), 0.1 to 1% (w/w), 0.1 to 0.3% (w/w), 0.3 to 10% (w/w), 0.3 to 3% (w/w), 0.3 to 1% (w/w), 1 to 10% (w/w), 1 to 3% (w/w) or 3 to 10% (w/w) of the final product.
[0061] In some embodiments, the sanitation agent comprises dimethyl benzyl ammonium chloride or dimethyl ethybenzyl ammonium chloride. In some embodiments, the sanitation agent comprises a mixture of dimethyl benzyl ammonium chloride or dimethyl ethybenzyl ammonium chloride. In some embodiments, the sanitation agent is a 1 : 1 mixture of dimethyl benzyl ammonium chloride or dimethyl ethybenzyl ammonium chloride.
[0062] In some embodiments, the sanitation agent is a quatanary amine and is added in an amount that constitutes 0.3 to 3% (w/w), 0.5 to 2% (w/w) or 0.5 to 1.5% (w/w) of the final product. In some embodiments, the sanitation agent is a quatanary amine and is added in an amount that constitutes about 1% (w/w) of the final product.
Use of Surfactants as Sanitation Agents Against Viruses
[0063] Surfactants concentrated above their critical micelle concentration (CMC) in aqueous solution form micellar aggregates. Because proteins are electrostatically diverse and possess hydrophobic, hydrophilic, anionic, and cationic regions, they can bind both anionic and cationic surfactants strongly. Surfactants with charged head groups can alter the effective surface charge of surfaces or particles by shielding opposite charges or adding charge to a hydrophobic site. The high surface activity of surfactants allows them to dictate protein stability and interactions.
[0064] Anionic surfactants at low concentrations reduce the magnitude of the apparent capsid surface charge enough to induce particle aggregation for capsids with a net negative surface charge. As the concentration of charged surfactant is increased beyond its CMC, the micelles can solubilize capsid protein dimers and therefore disassemble the capsid structure. Thus the surfactants are efficient in disrupting the virus structure only above their CMC, this
should be taken into account when formulating virus cleaning and disinfectant systems with surfactants. Surfactant micellization results in the ability of strong surfactants to disrupt interactions between virus capsid proteins and solubilize individual proteins or dimers. Virus particle disassembly by surfactant is likely to lead to complete loss of infectivity, which can also be severely disrupted by the dramatic apparent surface charge alteration and aggregation caused by ionic surfactant. Low concentrations of ionic surfactants (below CMC) are likely to disrupt the virus infectivity much less.
[0065] In a particular embodiment, anionic surfactants are used as a sanitation agent to destroy viruses. Typical anionic surfactants include soaps, sodium dodecylsulfate (SDS), alkylbenzene sulfonates, alkyl sulfonates, alkyl sulfonates, alkyl sulfates, salts of fluorinated fatty acids, silicones, fatty alcohol sulfates, polyoxyethylene fatty alcohol ether sulfates, a-olefin sulfonate, polyoxyethylene fatty alcohol phosphates ether, alkyl alcohol amide, alkyl sulfonic acid acetamide, alkyl succinate sulfonate salts, amino alcohol alkylbenzene sulfonates, naphthenates, alkylphenol sulfonate and polyoxyethylene monolaurate.
[0066] In a particular embodiment, SDS is used as a sanitation agent absorbed in the granular ceramic material. SDS (or sodium lauryl sulfate (SLS)), chemical formula NaChLLSSCL (IUPAC, 2014), is a tensioactive detergent agent. SDS possesses a zwitterionic form in aqueous solution with two distinct portions, polar and apolar, at opposite ends of a single molecule. The polar end is formed by a sulfate group while the opposite end, apolar, is composed by a long chain hydrocarbon, which may be linear, branched or aromatic according to the diluent solution. The chemical nature of SDS provides adequate ionic balance, solubilizing fats and oils, and the formation of microemulsions, hence it is suitable as an ingredient in cleaning products.
[0067] Direct contact of SDS with cells will cause physical and biochemical effects. In particular, SDS is able to undo the barrier capacity of the cellular membrane due to its effect on lipids. The effects of SDS depend on absolute concentrations and lipid/surfactant molar ratios. When in low concentrations of surfactants, cell membranes lose their barrier capacity increasing permeability. On the other hand, equal or superior surfactant/lipid ratios cause cell lysis. If levels of surfactant (SDS) exceed cytolytic concentrations, the lamellar structure of the membrane is solubilized releasing proteins, lipoproteins and micelles, resulting in a complete cell lysis. Similarly, when used in the context of decontamination of surfaces contaminated by viruses that have a lipid envelope, SDS, or other anionic surfactants are effective at breaking up the lipid envelope, and thereby ending viral infectivity.
The Modifying Agent
[0068] The modifying agent is added to the coated granular absorbent or the absorbed- and-coated granular absorbent in an amount to achieve desired physical characteristics (e.g., non-dusty and clump, ease of pick up, liquid loadability, etc.) in the final product. Examples of the modifying agent include, but are not limited to, thickening agents, gums, absorbent polymers, tackifiers, and combinations thereof.
[0069] As used herein, the term "thickening agent" may include any material known or otherwise effective in providing suspending, gelling, viscosifying, solidifying or thickening properties to the composition or which otherwise provide structure to the final product form. These thickening agents may include gelling agents, polymeric or nonpolymeric agents, inorganic thickening agents, or viscosifying agents. The amount and type of the thickening agent may vary depending upon the desired characteristics of the final product.
[0070] As used herein, the term “tackifier” refers to polymeric adhesives which increase the tack, i.e., the inherent stickiness or self-adhesion, of the compositions so that after a short period of gentle pressure they adhere firmly to surfaces. Examples of suitable tackifiers comprise high-flexibility resins such as, but not limited to, homopolymers of alkyl(meth)acrylates, especially alkyl acrylates, such as poly(isobutyl acrylate) or poly(2- ethylhexyl acrylate), linear polyesters, as commonly used for coil coating, linear difunctional oligomers, curable with actinic radiation, with a number average molecular weight of more than 2000, in particular from 3000 to 4000, based on polycarbonatediol or polyester-diol, linear vinyl ether homopolymers or copolymers based on ethyl, propyl, isobutyl, butyl and/or 2-ethylhexyl vinyl ether, or nonreactive urethane urea oligomers, which are prepared from bis(4,4- isocyanatophenyl)methane, N,N-dimethylethanolamine or diols such as propanediol, hexanediol or dimethylpentanediol.
[0071] In some embodiments, the modifying agent comprises a high-molecular substance that absorbs liquids, preferably water, swells, and finally is converted to a viscous true or colloidal solution.
[0072] In some embodiments, the modifying agent comprises one or more silicone gums. As used herein, the term "silicone gum" means a silicone polymer having a degree of polymerization sufficient to provide a silicone having a gum-like texture. In certain cases the silicone polymer forming the gum may be crosslinked.
[0073] In some embodiments, the modifying agent comprises a polymer. As used herein, Examples of the polymers include, but is not limited to, natural and synthetic polymers such as polyacrylamide (ACAM) and carboxymethyl cellulose.
[0074] In some embodiments, the polymers of the present application includes, but are not limited to, polyacrylates such as sodium polyacrylates, and carboxymethyl cellulose.
[0075] In some embodiments, the modifying agent comprises one or more superabsorbent polymer. The term “super-absorbent polymer” is understood to mean hydrophilic polymer structure capable of absorbing water or saline solution at greater than 10g of pure water/saline per gram of dry-based material (> lOg/g). Examples of super-absorbent polymers include, but are not limited to, sodium polyacrylates and carboxymethyl cellulose.
[0076] In some embodiments, the one or more modifying agents further comprise one or more additives selected from the group comprising denaturing agents, colorant agents, odor correctors, and/or pH regulators.
[0077] In some embodiments, the one or more modifying agents are added in an amount that constitute 0.1 to 5% (w/w), 0.1 to 2% (w/w), 0.1 to 1% (w/w), 0.1 to 0.3% (w/w), 0.3 to 5% (w/w), 0.3 to 2% (w/w), 0.3 to 1% (w/w), 1 to 5% (w/w), 1 to 2% (w/w) or 2 to 5% (w/w) of the final product.
The Cleaning Composition
[0078] Another aspect of the present application relates to a cleaning composition. The cleaning composition contains an granular absorbent material coated with a coating agent. Examples of the coating agent have been described above. In some embodiments, the coating agent contains a biocide. In some embodiments, the biocide comprises an agent selected from the group consisting of silanes, siloxanes, aminopropyltrimethoxysilane, quaternary amines, fumed metal hydroxides, silver and salts of silver, copper and salts of copper. In some embodiments, the biocide forms a static film on the surface of the granular absorbent material. In some embodiments, the granular absorbent material contains activated carbon, fumed silica, fine perlite, zeolites, processed clays or combinations thereof. In some embodiments, the coating agent constitutes 0.1 to 5% (w/w), 0.1 to 2% (w/w), 0.1 to 1% (w/w), 0.1 to 0.3% (w/w), 0.3 to 5% (w/w), 0.3 to 2% (w/w), 0.3 to 1% (w/w), 1 to 5% (w/w), 1 to 2% (w/w) or 2 to 5% (w/w) of the cleaning composition.
[0079] In some embodiments, the granular absorbent material contains ceramic minerals. In some embodiments, the granular absorbent material contains perlite and/or vermiculite. In some embodiments, the granular absorbent material has a surface area per mass ratio in the range of 100-10,000 m2/g, 100-9,000 m2/g, 100-8,000 m2/g, 300-8,000 m2/g, 1,000-8,000 m2/g, 2,000-8,000 m2/g, 3,000-8,000 m2/g, 4,000-8,000 m2/g, 5,000-8,000 m2/g, 6,000-8,000 m2/g, 7,000-8,000 m2/g, 100-7,000 m2/g, 300-7,000 m2/g, 1,000-7,000 m2/g, 2,000-7,000 m2/g, 3,000- 7,000 m2/g, 4,000-7,000 m2/g, 5,000-7,000 m2/g, 6,000-7,000 m2/g, 100-6,000 m2/g, 300-6,000 m2/g, 1,000-6,000 m2/g, 2,000-6,000 m2/g, 3,000-6,000 m2/g, 4,000-6,000 m2/g, 5,000-6,000 m2/g, 100-4,000 m2/g, 300-4,000 m2/g, 1,000-4,000 m2/g, 2,000-4,000 m2/g, 3,000-4,000 m2/g,
100-3,000 m2/g, 300-3,000 m2/g, 1,000-3,000 m2/g, 2,000-3,000 m2/g, 100-2,000 m2/g, 300- 2,000 m2/g, or 1,000-2,000 m2/g.
[0080] In some embodiments, the granular absorbent material has a surface area per mass ratio up to 10,000 m2/g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 9,000 m2/g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 8,000 m2/g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 7,000 m2/g. In some embodiments, the granular absorbent material has a surface area per mass ratio up to 6,000 m2/g.
[0081] In some embodiments, the granular absorbent material has a surface area per mass ratio of 100 m2/g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 300 m2/g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 1,000 m2/g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 2,000 m2/g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 3,000 m2/g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 4,000 m2/g or greater. In some embodiments, the granular absorbent material has a surface area per mass ratio of 5,000 m2/g or greater.
[0082] In some embodiments, the granular absorbent material has a surface area per mass ratio in the range of 1000-6,000 m2/g.
[0083] In some embodiments, the granular absorbent material has a surface area per volume ratio in the range of 100-5,000 m2/ml, 300-5,000 m2/ml, 1,000-5,000 m2/ml, 2,000-5,000 m2/ml, 3,000-5,000 m2/ml, 4,000-5,000 m2/ml, 100-4,000 m2/ml, 300-4,000 m2/ml, 1,000-4,000 m2/ml, 2,000-54,000 m2/ml, 3,000-4,000 m2/ml, 100-3,000 m2/ml, 300-3,000 m2/ml, 1,000- 3,000 m2/ml, 2,000-3,000 m2/ml, 100-2,000 m2/ml, 300-2,000 m2/ml, or 1,000-2,000 m2/ml.
[0084] In some embodiments, the granular absorbent material has a surface area per volume ratio up to 5,000 m2/ml. In some embodiments, the granular absorbent material has a surface area per volume ratio up to 4,000 m2/ml. In some embodiments, the granular absorbent material has a surface area per volume ratio up to 3,000 m2/ml.
[0085] In some embodiments, the granular absorbent material has a surface area per volume ratio of 100 m2/ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio of 300 m2/ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio of 1,000 m2/ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio of 2,000 m2/ml or greater. In some embodiments, the granular absorbent material has a surface area per volume ratio in the range of 1000-3,000 m2/ml.
[0086] In some embodiments, the granular absorbent material constitutes 10-70% (w/w), 10-60% (w/w), 10-50% (w/w), 10-40% (w/w), 10-30% (w/w), 10-20% (w/w), 20-70% (w/w), 20-60% (w/w), 20-50% (w/w), 20-40% (w/w), 20-30% (w/w), 30-70% (w/w), 30-60% (w/w), 30-50% (w/w), 30-40% (w/w), 40-70% (w/w), 40-60% (w/w), 40-50% (w/w), 50-70% (w/w), 50-70% (w/w) or 60-70% (w/w) of the cleaning composition. In some embodiments, the granular absorbent material constitutes 25-30% (w/w) of the final product. In some embodiments, the granular absorbent material constitutes about 27% (w/w) of the cleaning composition.
[0087] In some embodiments, the cleaning composition further comprises a sanitation agent absorbed in the coated granular absorbent material. Examples of the sanitation agent have been described above.
[0088] In some embodiments, the sanitation agent comprise an active substance designed to destroy, inhibit, reduce activity, inhibit grow or otherwise render harmless harmful organisms or toxic chemicals. In some embodiments, the sanitation agent is a liquid phase agent. In some embodiment, the sanitation agent is a liquid phase biocide. In some embodiment, the sanitation agent is a liquid phase chemical that inactivates toxic chemicals, such as chemo therapy drugs.
[0089] Examples of liquid phase biocide include, but are not limited to, chlorine bleach solutions, hydrogen peroxide solutions, peracetic acid, quaternary amine solutions, periodine, alcohol solutions, dimethyl benzyl ammonium chloride, dimethyl ethybenzyl ammonium chloride and mixtures thereof.
[0090] Examples of liquid phase chemicals that can be used to inactivate or remove toxic chemicals include, but are not limited to, anionic surfactants such as soap, sulfonates and sulfates. In some embodiments, large quantities of water is used to dilute the toxic chemicals.
[0091] In some embodiments, the sanitation agent constitutes 0.1 to 10% (w/w), 0.1 to 3% (w/w), 0.1 to 1% (w/w), 0.1 to 0.3% (w/w), 0.3 to 10% (w/w), 0.3 to 3% (w/w), 0.3 to 1% (w/w), 1 to 10% (w/w), 1 to 3% (w/w) or 3 to 10% (w/w) of the cleaning composition.
[0092] In some embodiments, the sanitation agent comprises dimethyl benzyl ammonium chloride or dimethyl ethybenzyl ammonium chloride. In some embodiments, the sanitation agent comprises a mixture of dimethyl benzyl ammonium chloride or dimethyl ethybenzyl ammonium chloride. In some embodiments, the sanitation agent is a 1 : 1 mixture of dimethyl benzyl ammonium chloride or dimethyl ethybenzyl ammonium chloride.
[0093] In some embodiments, the cleaning composition further comprises one or more modifying agent. Examples of the sanitation agent have been described above. In some embodiments, the modifying agent comprises a thickening agent, a tackifier, a gum, an absorbent polymers or combinations thereof. In some embodiments, the one or more modifying
agents comprise a carboxymethyl cellulose (CMC)-derived polymer and/or a hierarchically porous carbons (HPC)-derived polymer.
[0094] In some embodiments, the one or more modifying agents further comprise one or more additives selected from the group comprising denaturing agents, colorant agents, odor correctors, and/or pH regulators.
[0095] In some embodiments, the one or more modifying agents constitute 0.1 to 5% (w/w), 0.1 to 2% (w/w), 0.1 to 1% (w/w), 0.1 to 0.3% (w/w), 0.3 to 5% (w/w), 0.3 to 2% (w/w), 0.3 to 1% (w/w), 1 to 5% (w/w), 1 to 2% (w/w) or 2 to 5% (w/w) of the cleaning composition.
[0096] In some embodiments, the cleaning composition has a liquid loading capability in the range of 10-50% by volume, 15-45% by volume, 20-40% by volume, 25-35% by volume, or 25-30% by volume. In other embodiments, the cleaning composition has a liquid loading capability of 100-400% by mass addition, 150-350% by mass addition, or 200-300% by mass addition. In some embodiments, the cleaning composition of the present application is capable of absorbing liquid at a liquid loading of 25-30% by volume or 200-300% by mass addition.
[0097] In some embodiments, the cleaning composition is specifically designed to kill or inactivate enveloped viruses, such as coronaviruses. In some embodiments, the cleaning composition comprises ethyl alcohol, isopropyl alcohol, chlorine or hypochlorites, chlorine dioxide, sodium dichloroisocyanurate, and chloramine-T, formaldehyde, glutaraldehyde, hydrogen peroxide, iodophors, ortho-phthalaldehyde, peracetic acid, phenolics, quaternary ammonium compounds, or in conjunction with superoxidized water.
Method of Use
[0098] Another aspect of the present application relates to a method of using the cleaning composition of the present application. The method comprises the steps of applying an effective amount of the cleaning composition of the present application to a surface in need of cleaning, and remove the cleaning composition after a period of time.
[0099] In some embodiments, the period of time is from 30 seconds to 30 minutes. In some embodiments, the period of time is from 1 to 30 minutes, from 1 to 20 minutes, from 1 to 10 minutes, from 2 to 30 minutes, from 2 to 20 minutes, from 2 to 10 minutes, from 5 to 30 minutes, from 5 to 20 minutes and from 5 to 10 minutes.
[0100] In some embodiments, the surface in need of cleaning comprises a biohazard spill. In some embodiments, the biohazard spill is vomit, urine, blood, feces, and/or a chemo therapy drug. In some embodiments, the surface in need of cleaning is a surface in a public area and needs to be treated to prevent or reduce cross contamination or infection. As used herein, the term “public area” includes, but is not limited to, hospitals, doctors’ offices, urgent care facilities, nursing homes, prisons and related correction facilities, schools, buses, aircraft, airports, bars,
restaurants, hotels, amusement parks, any large gathering institution facilities, veterinary facilities and drug research and development facilities. In some embodiments, the public area is located in a hotel.
[0101] In some embodiments, the method further comprises the step of: washing the treated surface with a liquid or wiping the surface with a wiping material, such as paper tower or mops, after the removal of the cleaning composition.
[0102] Another aspect of the present application relates to a method of disinfecting an affected area to prevent or reduce the distribution of pathogens such as viruses and bacteria. The method comprises the steps of apply an effective amount of the cleaning composition of the present application to the affected area and remove the cleaning composition after a period of time, wherein the cleaning composition contains a granular absorbent material coated with a static, surface bonded film of biocide selected from the group consisting of silanes, siloxanes, aminopropyltrimethoxysilane, quaternary amines, fumed metal hydroxides, silver and salts of silver, copper and salts of copper. In some embodiments, the cleaning composition further comprises a sanitation agent selected from the group consisting of chlorine bleach solutions, hydrogen peroxide solutions, per acetic acid, quaternary amine solutions and alcohol solutions. In some embodiments, the sanitation agent is added to the cleaning composition immediately prior to the application to the affected area.
[0103] In some embodiments, the cleaning composition of the present application is a multi-phase product that can be used to kill microbes through a number of different mechanisms. In one embodiment, the composition is a doped granular ceramic disinfectant which combines a surface area static disinfectant or biocide coating with a chemical phase primary disinfectant or biocide absorbed in the ceramic particles. As used herein, the term “disinfectant” describes the composition and formulations described herein for the elimination of pathogens from surfaces. As used herein, the term "disinfect" shall mean the elimination of many or all pathogens on a surface to which disinfectant is administered.
[0104] In some embodiments, the cleaning composition of the present application is a surface area solid phase disinfectant that combines with a super absorbent polymer so that liquid loadings (e.g., 25-30% by volume/200-300% by mass addition) of available liquid can be added so as to impart chemical disinfection, to impart deodorizing chemicals or to impart a blanketing effect on the affected area so as to reduce the spread of microbe into the open air.
[0105] In some embodiments, the cleaning composition of the present application is a high surface area solid phase disinfectant with the addition of tackifiers, so that it lays on a bio hazard and forms a blanket which greatly reduces the release of airborne pathogens.
[0106] In certain embodiments, the cleaning composition is designed to be spray able on surfaces that may be contaminated with a virus. The blend of a sprayable cleaning composition can depend on the dispensing form (e.g., hose or trigger spray) and according to the surface that has to be decontaminated.
Decontamination of Surfaces Contaminated With Viruses
[0107] Surfaces likely to become contaminated with viruses include medical and veterinary areas that come into contact with blood, body fluids, or internal mucosae of humans and animals. In terms of risk of virus transmission, these are considered to be critical contacts or, when only mucosae are involved, semicritical. Environmental surfaces are designated as critical only if they are in areas where highly susceptible individuals are housed, e.g., neonatal intensive care units, bum units, operating suites, nursing care homes, etc.
[0108] Proper decontamination can only occur when there is direct contact for an adequate time between an appropriate concentration of cleaning composition and the virus. When contaminated surfaces are treated, then the nature and properties of the surface also become factors in the decontamination process. The presence of other substances with which the cleaning composition reacts influences both the degree of cleaning composition contact with the virus and the effective cleaning composition usage.
[0109] The surfaces which may be likely to carry contaminating viruses can be broadly categorized as nonporous inanimate, porous inanimate (e.g., linen), and animate (e.g., skin). Functionally, nonporous inanimate surfaces can be divided into instruments used for medical and veterinary procedures which are soaked in disinfectant solution between use, and environmental surfaces and objects which are usually decontaminated by wiping with towels, etc. Such surface may include everything from egg shells to cement, but, in practice, stainless steel, plastics, ceramics, glass, and painted surfaces are the most likely to be treated with decontaminants regularly.
[0110] When cleaning premises are attended by the public, frequently touched surfaces should be cleaned as often as possible (at least daily and if possible more frequently). Examples of these surfaces are doorknobs and door bars, chairs and armrests, tabletops, light switches, handrails, water taps, elevator buttons, etc. After ventilation, healthcare or other shared work areas should be carefully cleaned with a neutral detergent, followed by decontamination of surfaces using the cleaning composition. Cleaning of toilets, bathroom sinks and sanitary facilities need to be carefully performed, avoiding splashes. Decontamination with the cleaning composition should follow normal cleaning.
[oni] In some embodiments, the cleaning composition of the present application is used in a procedure specifically designed to kill or inactivate enveloped viruses, such as coronaviruses.
[0112] The following examples are offered by way of illustration of certain embodiments of aspects of the application herein. None of the examples should be considered limiting on the scope of the application.
Kits
[0113] Another aspect of the present application relates to a cleaning kit. The kit can be used for cleaning up hazardous materials, such as vomit, urine, blood, feces, and/or a spill of chemo therapy drug, or disinfecting a surface. In some embodiments, the kit contains the cleaning composition of the present application and instructions on how to use the cleaning composition.
[0114] In some embodiments, the kit further contains a copy of OSHA guidelines. In some embodiments, the kit further contains one or more of the following: biohazard bags, gloves, twist tie, antimicrobial hand wipe, germicidal wipe, scoop/scraper.
[0115] The cleaning kit can be conveniently placed in locations within quick reach of all caregivers. For example; all patient and chemotherapy rooms, case & crash carts, emergency vehicles, cafeteria, environmental services closets, and within or near first aid kits, etc. EXAMPLE 1: TESTS OF THE VIRUCIDAL EFFECT OF THE CLEANING COMPOSITION OF THE PRESENT APPLICATION
Grow VR-728 Feline calicivirus Strain F-9
[0116] Materials: CCL-94 cells, T-75 flask with CCL-94 cells, 70% confluent, 6 well plates with CCL-94 cells, 70% confluent, EMEM, FBS, VR-728 Feline calicivirus Strain F-9, 50ml conical tube, Serological pipette, stripettes, 35°C Incubator, CleanUp,
Methods
1. Viral stock = 1:10 dilution, 1ml virus + 9ml serum free EMEM
2. Remove medium from all flasks and plates
3. Add serum free media and virus to each flask and plat a. Flask 1 : 2ml virus + 8ml media b. Flask 2: 1.5ml virus + 8.5ml media c. Plate 1: virus + media in all 6 cells d. Plate 2
4. Incubate at 35°C for 1 !4 hours
5. Prepare media: EMEM + 2% FBS and filter
6. Add 15ml media to each flask
7. Add 1ml media to each well in each plate
Harvest VR-728 Feline calicivirus Strain F-9
1. Combine media from Flask 1 and 2 and Plate 1
2. Cells were divided into 10, 15ml conical tubes containing 10ml virus each
3. Store at -80°C
[0117] Materials: VR-728 Feline calicivirus Strain F-9, EMEM + 2% FBS, CleanUp, 6- well plates with CCL-94 Cells, 70% confluent, Beaker, 1.5ml centrifuge Tube, Centrifuge, 35°C incubator, Cell Scraper, Cell Counter
Methods
1. Virus diluted in EMEM + 2% FBS at 1:50.
2. Measure 2 sets of 2g, 3g, 4g, 5g, 6g of CleanUp and place each in a separate beaker. one set for 5minutes, and one set for lOminutes, autoclave.
3. Add 4ml virus to 6ml Cleaning Powder and allow it to sit for 5 minutes.
4. Remove Clean Up from each beaker.
5. Add 3ml media to each beaker.
6. Repeat steps 3-5 for 10 minutes.
7. Take 1ml from each beaker and add to a 1.5ml centrifuge tube. Centrifuge at 2200RPM, 4°C, 4 minutes.
8. Remove media from plate containing CCL-94 cells.
9. Add 30pl Clean Up and 3ml media to each well
10. Incubate for one hour.
11. Scrape Cells and place media into 15ml tubes.
12. Determine cell death
Plate Set-Up
Results
[0118] Compared to untreated virus samples, virus samples treated with CleanUp showed significantly reduced cytotoxicity, indicating activation of the virus by CleanUp. EXAMPLE 2: TESTS OF THE CLEANING COMPOSITION OF THE PRESENT APPLICATION WITH THE INITIAL VIRUCIDAL EFFECTIVENESS TEST
[0119] The virucidal effect of the cleaning composition of the present application is further tested using the Initial Virucidal Effectiveness Test protocol provided by the Antimicrobials Division of the United States Environmental Protection Agency (USEPA).
[0120] Briefly, this test is designed to validate virucidal effectiveness claims for a product to be registered as a virucide. It determines the potential of the test agent to disinfect hard, non-porous surfaces contaminated with NOROVIRUS. This test is designed to simulate consumer use, conforms to EPA Guidelines DIS/TSS-7, November 1981, and follows the general procedure outlined in the FR notice for another surrogate virus available onlinel and Virucidal Testing Format and Statistics Primer issued by EPA (March 2000).
[0121] TESTING CONDITIONS: Two lots of the test agents will be used to inactivate the challenge virus that has been dried on a sterile glass surface (two replicates for each batch/lot of the test agents). The test agent will be tested in a manner consistent with the label directions for use of the test agent or as specified by the Sponsor.
MATERIALS:
[0122] A. Test control and reference substances: supplied by the Sponsor (see last page). The test agent will be tested as supplied by the Sponsor unless directed otherwise. The Sponsor, before the initiation of testing, must specify all operations performed on the test agent such as dilutions of the test agent, the diluent for the test agent, or specialized storage conditions.
[0123] The test agent must be tested for identity, strength, purity, stability and uniformity as applicable. All unused test agent will be retained for a period after completion of the test, then discarded in a manner that meets the approval of the safety officer.
[0124] B. Materials can include, but are not limited to:
1. Challenge virus as requested by the sponsor of the study: Feline calicivirus (American Type Culture Collection, Manassas, VA; ATCC VR-782).
2. Host cell line: Crandel Reese Feline Kidney (CRFK) cell (American Type Culture Collection, Manassas, VA; ATCC CCL-94). ). CRFK cells will be grown in Cell Culture Media (Eagle’s Minimum Essential Media containing $5% Fetal Bovine Serum) containing Fetal Bovine Serum (FBS). The FCV will be grown by inoculating confluent cell monolayers, no more than 24-48 hours in age, using low multiplicity of infection (MOI). Briefly, a flask of host cells grown in cell culture media containing 10% fetal bovine serum (FBS) will be used. The
percent FBS contained in the stock virus aliquot will be adjusted to yield a minimum of a 5% organic soil load. Cells will be washed three times with phosphate buffered saline (PBS) and inoculated with virus. Post-virus adsorption, the cell monolayer will be washed once in Earle’s balanced salt solution (EBSS), re-fed with cell culture media and incubated. The cytopathic effects (CPE) will be described as small, rounding of the cells, with a slight granular look. The CPE will start to develop in 1-2 days following inoculation, and will be harvested when more than 90% cytopathic effects (CPE) are observed. Post-incubation, the cells will be disrupted, with cell debris removed by centrifugation. Stock virus will be prepared by collecting the supernatant culture fluid from 75-100% infected culture cells. The supernatant will be removed, aliquoted, and stored in an ultra-low temperature freezer until the day of use. On the day of use an aliquot will be removed, thawed and refrigerated until use in the assay.
3. Laboratory equipment and supplies, and
4. Media and reagent: a. Cell Culture Media (Eagle’s Minimum Essential Media containing $5% Fetal Bovine Serum) b. Earle’s Balanced Salt Solution (EBSS) c. Fetal Bovine Serum (FBS) d. Phosphate Buffered Saline (PBS) e. Sephadex™/Sephacryl™ columns (if necessary) f Neutralizer
[0125] TEST SYSTEM IDENTIFICATION: All Petri dishes, dilution tube racks, and host-containing apparatus will be labeled with the following information: virus, host, test agent, and project number.
EXPERIMENTAL DESIGN:
[0126] A. Inoculum preparation: The F-9 strain of Feline calici virus (FCV) will be obtained from the American Type Culture Collection, Manassas, VA, (ATCC VR-782). The FCV will be grown by inoculating confluent cell monolayers, no more than 24-48 hours in age, using low multiplicity of infection (MOI). Briefly, a flask of host cells grown in cell culture media containing 10% fetal bovine serum (FBS) will be used. Cells will be washed three times with phosphate buffered saline (PBS) and inoculated with virus. Post-virus adsorption, the cell monolayer will be washed once in Earle’s balanced salt solution (EBSS), re-fed with cell culture media and incubated. The cytopathic effects (CPE) are described as small, rounding of the cells, with a slight granular look. The CPE starts to develop in 1-2 days following inoculation, and will be harvested when more than ninety percent cytopathic effects (CPE) are observed. Postincubation, the cells will be disrupted, with cell debris removed by centrifugation.
[0127] Stock virus will be prepared by collecting the supernatant culture fluid from 75- 100% infected culture cells. The supernatant will be removed, aliquoted, and stored in an ultralow temperature freezer until the day of use. On the day of use an aliquot is removed, thawed and refrigerated until use in the assay. The percent FBS contained in the stock virus aliquot is adjusted to yield a minimum of a 5% organic soil load. If the Sponsor chooses a soil load greater than 5%, the percent FBS contained in the stock virus aliquot will be adjusted to yield the percent soil load requested.
[0128] B. Carrier Preparation: An aliquot of 0.2 ml stock virus will be spread uniformly over the bottoms of 100 X 15 mm sterile glass Petri dishes with a cell scraper. The virus will be air-dried at room temperature for 30-60 minutes (until visibly dry). The drying conditions (temperature and humidity) will be appropriate for the test virus to obtain maximum survival following drying. The actual drying time and temperature will be recorded. Two carriers will be prepared for each lot of test agent and plate recovery control. Additionally, one carrier per test agent lot will be prepared for the neutralizer effectiveness control using cell culture media in place of stock virus.
[0129] C. Test agent preparation: The test agent will be prepared and used according to the Sponsor’s directions or proposed label claims.
[0130] D. Test: For each of two batches of test substance, two dried virus films will be exposed to 2.0 ml of the use dilution of the test substance, or to the amount of spray released under use conditions (spray products) for a specified exposure time and temperature. Post contact time, the test agent will be neutralized and the mixture will be scraped from the surface of the dish. This will be considered approximately one log10 dilution.
[0131] 1. Sephadex™/Sephacryl™ Filtration. If columns are utilized, each sample will be loaded into individual pre-spun Sephadex™/Sephacryl™ columns. Virus-test substance mixture will be passed through individual columns utilizing the syringe plunger or centrifugation in order to detoxify the mixture. The aseptically collected samples will be diluted as appropriate.
[0132] 2. If columns are not used, serial tenfold dilutions of neutralized virus will be prepared in cell culture media. For spray -type agents, the agent will be used as per Sponsor’s instructions, the volume produced by the spray product during the spraying application specified by the sponsor will be measured prior to testing and an equivalent quantity of the neutralizer will be applied post contact time. Following application of the test agent, contact time, and neutralization, the procedure for processing the samples will the same as described earlier (see above).
[0133] E. Infection, cell maintenance and infectivity assays: Selected dilutions of the neutralized inoculum/test agent mixture will be added to cultured cell monolayers. Four wells per dilution will be added to the host cell monolayers and incubated at 37±2°C in 5±1% CO2 for 5-7 days. Post incubation the infectious FCV will be scored microscopically by observing virusspecific cytopathic effects (CPE) produced by replicating infectious virus. The CPE associated with FCV is visually evidenced under the microscope by the presence of small, shrinking cells that have detached from the monolayer. These changes will be scored in comparison with the negative control (cell viability control).
[0134] F. Controls: All controls will be performed at the same time as the test, incubated under the same conditions and assayed in the same manner as the test (see above). Neutralizer effectiveness control, Cytotoxicity control and Cytotoxicity-related viral interference control will be performed for test agent(s).
[0135] 1. Cell viability control. This control will demonstrate that cells remain viable throughout the course of the assay period. In addition, it will confirm sterility of the cell culture employed throughout the assay period. Four wells will receive cell culture media only.
[0136] 2. Virus stock titer. The challenge virus will be titered at the time of the test to determine the relative infectivity of the virus and to demonstrate the susceptibility of the host cells to support infection of FCV. The virus inoculum will be serial diluted tenfold in cell culture media. Selected dilutions will be inoculated into four wells per dilution and incubated under the same conditions as the test.
[0137] 3. Plate recovery control (PRC). Two ml of cell culture media will be added to the dried virus. Post-contact time, the virus/cell culture mixture will be subjected to the identical neutralization procedure as the test agent. If columns are used, a portion of the virus/cell culture media/neutralizer mixture will be used for the column titer control (see below). This control will determine the relative loss in virus infectivity resulting from drying and neutralization alone. The results from the PRC will be compared with the test results to confirm recovery of at least four log10 of infectious virus following drying and neutralization. Its titer will be used to compare with the titers of the test results to reach the acceptable test criteria (see below).
[0138] 4. Neutralizer effectiveness control (NEC). The neutralization procedure will be dependent upon the active ingredient present in the test agent and in the internal control test agent. For this control, each lot of the test agent will be processed exactly as the test procedure, but instead of the viral inoculum, cell culture media will be added. Post neutralization, the sample will be divided into three portions [two for cytotoxicity related controls (see below) and one for neutralizer effectiveness].
[0139] If columns are used, each sample will be passed through individual columns and the eluate will be serial diluted as appropriate in cell culture media. If columns are not used, the neutralizer effectiveness samples will be serial diluted tenfold in cell culture media. The diluted samples will be mixed with low titer virus, held for a period equivalent to contact time and assayed for viral infectivity and/or cytotoxicity (see below), in order to determine the dilution of test agent at which virucidal activity, if any, is retained. Then the selected dilutions will be used to inoculate host cells as described for the test procedure. Dilutions that show virucidal activity will not be considered in determining reduction of viral infectivity by the test agent.
[0140] 5. Cytotoxicity control (CT). A CT control will be run to determine if the product is toxic to the cells. Each lot of the neutralized test agent will be run to determine cytotoxicity. The CT sample, acquired from the NEC, will be serial diluted tenfold in cell culture media, having no virus added. Selected dilutions will be inoculated and incubated in the same manner as the test and control samples.
[0141] G. Calculations. Viral and cytotoxicity titers will be expressed as -log10 of the 50 percent titration endpoint infectivity (TCID50), respectively, as calculated by the method of Spearman Karber. st
[0142] -Log of 1 dilution inoculated -[(Sum of % mortality at each dilution/100) - 0.5) x (logarithm of dilution)]
[0143] The log10 reduction in infectivity will be calculated using the revised EPA approved method for calculating the Most Probable Number (MPN) as obtained from the EPA on January 4, 2001.
EXAMPLE 3: TESTING OF EFFICACY IN DIFFERENT ENVIRONMENTS AND
AGAINST MULTIPLE PATHOGENS
[0144] The cleaning composition of the present application is tested for effectiveness according to EPA standard operating procedures to measure the effectiveness of hard surface disinfectants against Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella choleraesuis , Mycobacterium bovis, Clostridium difficile, and viruses. The standard operating procedures are based on strict interpretations of AO AC International and ASTM International standard methods.
[0145] In an exemplary test, the cleaning composition of the present application is tested as a germicidal spray product with testing for effectiveness against Staphylococcus aureus, Pseudomonas aeruginosa and Salmonella enterica (EPA Method ID: MB-06-08 dated 9/22/2014).
[0146] Test cultures of the bacterium are prepared as follows: Defrost a single cryovial at room temperature and briefly vortex to mix. Add 10 pL of the thawed frozen stock (single use) to a tube containing 10 mL of culture medium (Synthetic broth is used for 5. aureus, P. aeruginosa and S. enterica. Nutrient broth may be used for P. aeruginosa.'). Vortex, and incubate at 36 ± 1°C for 24 ± 2 h. One daily transfer is required prior to the inoculation of a final test culture. Daily cultures may be subcultured for up to 5 days; each daily culture may be used to generate a test culture. For S. aureus and S. enterica only, briefly vortex the 24 h cultures prior to transfer. For the final subculture transfer, inoculate a sufficient number of 20 * 150 mm tubes containing 10 mL growth medium (e.g., synthetic broth or nutrient broth) with 10 pL per tube of the 24 h culture then vortex to mix. Incubate 48-54 h at 36 ± 1°C without shaking.
[0147] Carrier inoculation is carried out as follows: Inoculate approximately 80 carriers; 60 carriers are required for testing, 6 for control carrier counts, and 1 for the viability control. For P. aeruginosa, remove the pellicle from the broth either by decanting the liquid aseptically into a sterile tube, by gently aspirating the broth away from the pellicle using a pipette, or by vacuum removal. Avoid harvesting pellicle from the bottom of the tube. Transfer test culture after pellicle removal into sterile 25 * 150 mm test tubes (up to approximately 20 mL per tube) and visually inspect for pellicle fragments. Presence of pellicle in the final culture makes it unusable for testing.
[0148] For S. aureus and S. enterica, using a vortex-style mixer, mix 48-54 h test cultures 3-4 s and let stand 10 min at room temperature before continuing. Remove the upper portion of each culture (e.g., upper % or approximately 7.5 mL), leaving behind any debris or clumps, and transfer to a sterile flask; pool cultures in the flask and swirl to mix.
[0149] For S. aureus, P. aeruginosa and S. enterica, using a vortex-style mixer, mix 48- 54 h test cultures 3-4 s and let stand 10 min at room temperature before continuing. Remove the upper portion of each culture (e.g., upper % or approximately 7.5 mL), leaving behind any debris or clumps, and pool culture into a sterile flask; swirl to mix. Measure and record the OD at 650 nm. Use sterile broth medium to calibrate the spectrophotometer. Note: To achieve mean carrier counts within the appropriate range (see section 8), the final test culture may be diluted (e.g., one part culture plus one part sterile broth) prior to the addition of the OSL to the inoculum using the sterile culture medium used to generate the final test culture (e.g, synthetic broth). Use the diluted test culture for carrier inoculation within 30 min. Add appropriate amount of organic burden if required. Swirl to mix.
[0150] Vortex-mix the inoculum periodically during the inoculation of carriers. Use a calibrated positive displacement pipette to transfer 0.01 mL of the culture to the sterile test carrier in the Petri dish. Immediately spread the inoculum uniformly using a sterile loop. Do not
allow the inoculum to contact the edge of the glass slide carriers. Cover dish immediately. Dry carriers in incubator at 36 ± 1°C for 30-40 min. Perform efficacy testing within two hours of drying.
[0151] Enumeration of viable bacteria from carriers (control carrier counts) is conducted as follows: Assay dried carriers in 2 sets of three carriers, one set immediately prior to conducting the efficacy test and one set immediately following the test. Randomly select 6 inoculated carriers for carrier count analysis prior to efficacy testing. Place each of the inoculated, dried carriers in a 38 x 100 mm culture tube or sterile 50 mL polypropylene conical tube containing 20 mL of letheen broth. Vortex immediately - 60 ± 5 seconds for P. aeruginosa or 120 ± 5 seconds for S. aureus and S. enterica. After vortexing, briefly mix and make serial ten-fold dilutions in 9 mL dilution blanks of PBDW. Briefly vortex and plate 0.1 mL aliquots of appropriate dilutions in duplicate on TSA or BAP using spread plating. Plate appropriate dilutions to achieve colony counts in the range of 30-300 colony forming units (CFU) per plate. Spread inoculum evenly over the surface of the agar. Plates must be dry prior to incubation. If the serial dilutions are not made and plated immediately, keep the tubes at 2-5°C until this step can be done. Complete the dilutions and plating within 2 h after vortexing. Alternatively, pool the letheen broth from the tubes with the carriers and briefly vortex. Serially dilute and plate 0.1 mL aliquots of the pooled media (60 mL). The average carrier count per set will be calculated. Incubate plates (inverted) at 36 ± 1°C for up to 48 ± 2 h. Count Colonies.
[0152] Disinfectant sample preparation is conducted as follows: For aerosol cans and trigger or pump sprayers, shake the can 25 times prior to use, unless otherwise specified by the manufacturer. Spray the test substance for 10-15 seconds prior to testing to ensure sprayer is operating correctly and test substance is dispensed properly. For concentrated test substances, aseptically prepare the test substance use-dilution required for the test using appropriate sterile glassware or pipettes. For concentrated test substances, use > 1.0 mL or 1.0 g of the test substance sample to prepare the final solution to be tested. Use v/v dilutions for liquid test substances and w/v dilutions for solids. Prior to testing, wipe the spray nozzle using 70% ethanol and sterile gauze and allow to dry.
[0153] The test procedure is conducted as follows: After the required carrier drying time, spray the slides sequentially for a specified time, distance, and number of pumps at timed intervals (typically 30 seconds) with the carriers in a horizontal position. Use a certified timer to time the spray interval. Spray the slide within ±5 seconds of the specified time for a contact time of 1-10 minutes or within ±3 seconds for contact times <1 minute. After spraying, maintain the carriers in a horizontal position. Treated carriers must be kept undisturbed during the contact time. After the last slide of a set (typically 20 slides) has been sprayed with the disinfectant, and
the exposure time is complete, sequentially transfer each slide into the primary subculture tube containing the appropriate neutralizer within the ±5 second time limit. Drain the excess disinfectant from each slide prior to transfer into the neutralizer tube. Drain carriers without touching the Petri dish or filter paper. Perform transfers with flame sterilized or autoclaved forceps. The slide can touch both the interior sides of the Petri dish and the subculture tube during the transfer, but avoid this contact as much as possible. After the slide is deposited, recap the subculture tube and shake culture thoroughly. Incubate at 36 ± 1°C for 48 ± 2 h.
[0154] Results are recorded as follows: Gently shake each tube prior to recording results. Record results as + (growth) or 0 (no growth) as determined by presence or absence of turbidity. Confirm a minimum of three positive carrier sets per test. If there are less than three positive carriers, then confirm each carrier.
[0155] The cleaning composition of the present application is tested against the parameters set by the EPA in the Series 810 — Product Performance Test Guidelines, specifically public health uses of disinfectants (OCSPP 810.2200 (EPA-HQ-OPPT-2009-0150-0029)). To demonstrate efficacy, testing is conducted against Salmonella enterica (S. enterica), formerly designated as Salmonella choleraesuis , American Type Culture Collection (ATCC) 10708 for effectiveness against Gram-negative bacteria, or Staphylococcus aureus (S. aureus) (ATCC 6538) for effectiveness against Gram-positive bacteria. Three batches of the product are tested at the lower certified limit (LCL). For each batch, sixty carriers are used in the test. Three independent tests (i.e., three batches tested once on three different test days) are conducted against the test microbe at the LCL. The performance standard for 5. aureus is 0-3 positive carriers out of sixty. The performance standard for 5. enterica is 0-1 positive carriers out of sixty. Contamination of one carrier (culture tube) is allowed per 60-carrier set; occurrence of more than one contaminated carrier invalidates the test results. For germicidal spray products, the product should kill the test microorganisms on 59 out of each set of 60 carriers/slides. Contamination of only one carrier (culture tube) is allowed per 60-carrier set; occurrence of more than one contaminated carrier invalidates the test results.
[0156] For use as a hospital or healthcare disinfectant, to demonstrate efficacy, testing is conducted against S. aureus (ATCC 6538) and Pseudomonas aeruginosa (ATCC 15442). For use against fungus, to demonstrate efficacy, testing is conducted against Trichophyton mentagrophytes (ATCC 9533). For use against viruses, testing is conducted against Hepatitis B virus, Hepatitis C virus, and Norovirus, the Duck Hepatitis B virus, Bovine Viral Diarrhea virus, and Feline Calicivirus, respectively, which are considered acceptable surrogates for testing.
EXAMPLE 4: USE OF CLEANING COMPOSITION TO DECONTAMINATE
AREAS CONTAMINATED WITH ENVELOPED VIRUSES, E G., CORONAVIRUS
Coronavirus
[0157] Coronaviruses are enveloped viruses with a positive-sense single-stranded RNA genome and a nucleocapsid of helical symmetry. Coronavirus virions are generally considered to have on average diameters of 80-120 nm, but the size range can vary from 50 nm up to 200 nm. Characteristic surface spikes or peplomers, which appear club-like, pear-shaped, or petalshaped, project some 17-20 nm from the virion surface, having a thin base that swells to a width of about 10 nm at the distal extremity. In certain coronaviruses a second set of projections, 5- 10-nm long, forms an undergrowth beneath the major spikes.
[0158] Coronavirus infections begin with the binding of virions to host cellular receptors. The infection culminates in the deposition of the nucleocapsid into the cytoplasm, where the viral genome becomes available for translation. The positive-sense genome, which functions in effect as the first mRNA of viral infection, is translated into the enormous replicase polyprotein. The replicase then uses the genome as the template for the synthesis, via negativestrand intermediates, of both new viral genomes and a set of subgenomic mRNAs. The latter are translated into structural proteins and accessory proteins. The membrane-bound structural proteins, M, S, and E, are inserted into the ER, from where they transit to the endoplasmic reticulum-Golgi intermediate compartment (ERGIC). Nucleocapsids are formed from the encapsidation of progeny genomes by N protein, and these coalesce with the membrane-bound components, forming virions by budding into the ERGIC. Finally, progeny virions are exported from infected cells by transport to the plasma membrane in smooth-walled vesicles, or Golgi sacs, that remain to be more clearly defined. During infection by some coronaviruses, but not others, a fraction of S protein that has not been assembled into virions ultimately reaches the plasma membrane. At the cell surface S protein can cause the fusion of an infected cell with adjacent, uninfected cells, leading to the formation of large, multinucleate syncytia. This enables the spread of infection independent of the action of extracellular virus, thereby providing some measure of escape from immune surveillance.
SARS-CoV-2
[0159] Coronaviruses have widely been known to cause respiratory and intestinal infections in humans after the outbreak of “severe acute respiratory syndrome (SARS).” SARS was caused by SARS-CoV, and was followed by “Middle East respiratory syndrome (MERS)” caused by MERS-CoV. The outbreak of COVID-19 is caused by a coronavirus named SARS- CoV-2 (due to its similarity to SARS-CoV). SARS-CoV infects ciliated bronchial epithelial cells and type-II pneumocytes through angiotensin-converting enzyme 2 (ACE2) as receptor; mechanism of action for SARS-CoV-2 are still being determined.
[0160] It has been estimated the environmental stability of SARS-CoV-2 is up to three hours in the air post-aerosolisation, up to four hours on copper, up to 24 hours on cardboard and up to two to three days on plastic and stainless steel. These findings are similar to results obtained for environmental stability of SARS-CoV-1.
[0161] SARS-CoV-2 has been detected in environmental samples from COVID-19 dedicated intensive care units (ICU) in hospitals. In rooms of COVID-19 patients, different levels of environmental contamination have been detected, ranging from 1 out of 13 to 13 out of 15 samples testing positive for SARS-CoV-2 prior to cleaning. One sample from an air exhaust outlet was positive indicating that virus particles may be displaced by air and deposited on surfaces, although no direct air samples tested positive. SARS-CoV-2 was also detected on objects such as the self-service printers used by patients to self-print the results of their exams, desktop keyboards and doorknobs. Virus was detected most commonly on gloves and, even rarely, on eye protection. The evidence shows the threat of contamination of SARS-CoV-2 in the environment of a COVID-19 patient, therefore reinforcing the need for decontamination of these environments. The cleaning composition described herein provides an effective solution. Decontamination Protocol
[0162] Appropriate personal protective equipment is worn for cleaning up a body fluid spill. Gloves are worn during the cleaning and decontaminating procedures. To avoid the consequences of any splashing, the worker wears a face shield and gown. For large spills, overalls, gowns or aprons as well as boots or protective shoe covers are worn. Personal protective equipment is changed if tom or soiled, and is always removed before leaving the location of the spill, and then hands are washed.
Protocol:
1. WASH hands and put on gloves.
2. Don a face shield and gown. For large spills, overalls, gowns or aprons as well as boots or protective shoe covers are worn.
3. The cleaning composition is applied to spill - wait at least 60 seconds.
4. Disposable towels are used to spread the cleaning composition to any areas not covered by initial application of the cleaning composition. Paper towels are disposed in plastic-lined waste receptacles
5. The surface is sprayed or wiped thoroughly with the cleaning composition -the appropriate contact time is allowed to pass in accordance with the degree of severity of the spill (typically 1 - to 5 minutes).
6. The cleaning composition is wiped up disposable paper towels. Paper towel are discarded as above.
7. Remove gloves and dispose in plastic-lined waste receptacle.
8. WASH hands.
[0163] The following active ingredients are some of those that are incorporated in the sanitation agent in the cleaning composition in combinations of one or more ingredients for use in decontamination of areas suspected of harboring SARS-CoV-2: quaternary ammonium; isopropanol; dodecylbenzenesulfonic acid; lactic acid; hydrogen peroxide; citric acid; chlorine dioxide; sodium hypochlorite; L-lactic acid; citric acid; thymol; peroxyacetic acid; potassium peroxymonosulfate; sodium chloride; thymol; ethanol; glutaraldehyde; phenols; sodium dischloroisocyanurate dehydrate; hypochlorous acid; silver; peroxy octanoic acid; sodium carbonate peroxyhydrate; sodium dichloro-S-triazinetrione; potassium peroxymonosulfate; ethyl alcohol; octanoic acid; glycolic acid; ammonium carbonate; ammonium bicarbonate.
[0164] While various embodiments have been described above, it should be understood that such disclosures have been presented by way of example only and are not limiting. Thus, the breadth and scope of the subject compositions and methods should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.
[0165] The above description is for the purpose of teaching the person of ordinary skill in the art how to practice the object of the present application, and it is not intended to detail all those obvious modifications and variations of it which will become apparent to the skilled worker upon reading the description. It is intended, however, that all such obvious modifications and variations be included within the scope of the present application, which is defined by the following claims. The aspects and embodiments are intended to cover the components and steps in any sequence, which is effective to meet the objectives there intended, unless the context specifically indicates the contrary.
Claims
1. A method for prevention and/or decontamination of a surface from a virus, comprising the steps of: applying an effective amount of cleaning composition on said surface, wherein said cleaning composition comprises a granular absorbent material coated with a biocide; and a sanitation agent absorbed in said granular absorbent material, wherein said sanitation agent comprises a surfactant.
2. The method of Claim 1, said virus effects one or more of the nervous system, musculo-skeletal system, digestive system, hematological systems, immune systems, or respiratory systems, or wherein said virus is one of more selected from the group consisting of norovirus, HIV, rotavirus, adenovirus, astrovirus, coronavirus, hepatitis virus, ebola virus, arenaviruses, bunyaviruses, filoviruses, arenaviruses, Nipah virus and hantavirus.
3. The method of Claim 2, said coronavirus is SARS-CoV-2.
4. A method of formulating a cleaning composition for prevention and/or decontamination of a surface from a virus according to the method of Claims 1-3, comprising the steps of: coating a granular absorbent material with a coating agent to produce a coated absorbent material, wherein the coating agent comprises a biocide, and wherein the coating agent forms a surface bonded film on the granular absorbent material; and mixing the coated absorbent material with a sanitation agent, wherein the coated absorbent material absorbs the sanitation agent to form the cleaning composition, wherein the sanitation agent comprises a surfactant, and wherein the sanitation agent is an anionic surfactant.
5. The method of Claim 4, further comprising the step of: grinding an absorbent material to produce the granular absorbent material used in the coating step.
6. The method of Claims 4-5, wherein the granular absorbent material is coated with a layer of surface bonded biocide by vapor deposition, pressure micro droplet spray or fuming or fogging nozzle.
7. The method of Claims 4-6, wherein the granular absorbent material is selected from the group consisting of ceramic minerals, zeolite, activated carbon, fumed silica, processed clays, cellulosic absorbents, fibrous absorbents and combinations thereof.
8. A cleaning composition a cleaning composition for prevention and/or decontamination of a surface from a virus according to the method of Claims 1-3, comprising: a granular absorbent material coated with a biocide, wherein the biocide forms a surface bonded film on the granular absorbent material; and
- 35 -
a sanitation agent absorbed in said granular absorbent material, wherein said sanitation agent comprises a surfactant.
9. The cleaning composition of Claim 8, wherein the granular absorbent material is selected from the group consisting of ceramic minerals, zeolite, activated carbon, fumed silica, processed clays, cellulosic absorbents, fibrous absorbents and combinations thereof.
10. A sanitation method for decontamination against viruses, comprising the step of: applying an effective amount of the cleaning composition of Claims 8-9 to a surface in need of sanitation; and removing the cleaning composition after a period of time.
11. A cleaning kit for decontaminating against viruses, comprising: the cleaning composition of Claims 8-9, and instructions on how to use the cleaning composition.
12. The cleaning kit of Claim 11, further comprising one or more items selected from the group consisting of biohazard bags, gloves, twist tie, antimicrobial hand wipe, germicidal wipe, scoops and scrapers.
- 36 -
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2020/054768 WO2022075991A1 (en) | 2020-10-08 | 2020-10-08 | Anti-viral cleaning composition, method of making and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4225036A1 true EP4225036A1 (en) | 2023-08-16 |
Family
ID=81127036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20956890.6A Pending EP4225036A1 (en) | 2020-10-08 | 2020-10-08 | Anti-viral cleaning composition, method of making and use thereof |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4225036A1 (en) |
WO (1) | WO2022075991A1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9818778D0 (en) * | 1998-08-28 | 1998-10-21 | Crosfield Joseph & Sons | Particulate carrier for biocide formulations |
US8343525B2 (en) * | 2009-12-22 | 2013-01-01 | Becton, Dickinson And Company | Chlorhexidine acetate antiseptic cleaning agent |
US10604729B2 (en) * | 2016-09-08 | 2020-03-31 | Morehouse School Of Medicine | Liquid loading composition, method of making and use thereof |
US10757988B1 (en) * | 2020-04-07 | 2020-09-01 | Molecular Rebar Design, Llc | Personal protective equipment with functionalized nanotube compositions to control pathogens such as SARS CoV-2 (coronavirus) |
-
2020
- 2020-10-08 EP EP20956890.6A patent/EP4225036A1/en active Pending
- 2020-10-08 WO PCT/US2020/054768 patent/WO2022075991A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022075991A1 (en) | 2022-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11485939B2 (en) | Anti-viral cleaning composition, method of making and use thereof | |
AU2019232810B2 (en) | Cleaning composition, method of making and use thereof | |
US11162058B2 (en) | Liquid loading composition, method of making and use thereof | |
EP4225036A1 (en) | Anti-viral cleaning composition, method of making and use thereof | |
WO2022239605A1 (en) | Virucidal agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230505 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |